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Abstract
Over 30 years of antiretroviral therapy (ART) has transformed human
immunodeficiency virus type one (HIV-1) outcomes from certain death to a nearly
complete and normal life [1]. Though disease growth has slowed, the virus still
creates substantial co-morbid diseases as well as social and economic burdens
worldwide [2]. Lack of success with curative efforts combined with shortcomings
in global treatment remain to be properly addressed. The requirement for daily
use of combination antiretroviral drugs (ARVs) in low to middle income countries where the majority of the HIV-1 positive population resides - can lead to breaks in
regimen adherence due to a lack of access to ARV, high cost, social stigma, and
lack of disease awareness [3]. Treatment breaks speed viral drug resistance and
longer-term adverse events, ultimately shortening patient life-span.

Hospital

feedback in low to middle income countries indicates patient preference for a
variety of treatment options, including long-acting (LA) strategies [4]. The need for
treatment and by extension curative options is paramount in HIV-1 research. With
an eye toward the future of HIV treatment, our laboratories generated a platform
for small molecule antiretroviral drug nanoformulations by creating potent
hydrophobic lipophilic ARV prodrugs with stable long-term physicochemical
properties [5, 6]. Herein, this platform is extended to multiple small molecule
inhibitors intended for antiviral therapy and HIV-1 eradication. A small molecule
inhibitor used in cancer treatment was chemically modified to prolong drug activity,
then tested for anti-HIV activities in the context of immune therapy in curative
efforts. Additionally, two nucleoside reverse transcriptase inhibitors (NRTI) were

chemically modified to produce long-acting drug iterations. Prodrug nuceloTide
(ProTide) technology was used to chemically alter the NRTIs. A tenofovir ProTide
was constructed and formulated, increasing prodrug accumulation. Following the
same strategy, a phosphoroamidate prodrug nucleotide (ProTide) of lamivudine
(3TC), called (M23TC) was synthesized and nanoformulated (NM23TC). A single
treatment of NM23TC in human monocyte-derived macrophages (MDM) with
NM23TC showed increased drug uptake, retention, intracellular 3TC triphosphate
(3TC-TP) and sustained antiretroviral activities for 30 days.

Pharmacokinetic

analysis of NM23TC administered to Sprague Dawley rats showed sustained
prodrug levels in blood and tissues. Further, in vitro studies showed intact prodrug
was released over a month from MDMs. When tested in CEM CD4+ T cells, the
prodrug was shown to rapidly convert to its 3TC-TP. Taken together, a putative
mechanism for extended delivery of active compound to viral cell targets was
constructed. This mechanism was strongly supported when tested as a broadspectrum agent in model for hepatitis B virus infection in humanized mice. A single
intramuscular injection produced sustained antiviral activities for one month. Taken
together, the approaches give validation to potential value of the platform of
transforming daily medications into nanoformulated prodrugs for long-acting
antiviral activities.
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Chapter 1
Background and Significance

2
1.1 Global Impact and Challenges of the Human Immunodeficiency Virus
Since its discovery in 1983, human immunodeficiency virus one (HIV-1) –
the virus that causes acquired immune deficiency syndrome (AIDS) – has infected
nearly 80 million people. Currently, nearly 40 million people are infected with HIV1, with just under 1 million people dying from HIV-related illnesses in 2017 (Figure
1) [7]. Without treatment, all HIV-1 clades and subtypes become fatal on average
after 9-11 years [8]. Current treatment for HIV-1, termed antiretroviral therapy
(ART), was initially developed in 1987. Over 30 years later, there is now a highly
effective large library of antiretroviral drugs (ARVs) that effectively normalizes a
person’s lifespan, provided treatment adherence [9]. Despite an evening-out or
slight decline in new HIV-1 cases in many areas globally, the disease remains a
substantial social and economic burden. Roughly 75% of AIDS-infected patients
reside in low to middle income countries.

In these countries, a substantial

percentage of infected people remain undiagnosed [10, 11].

Global

considerations preventing HIV elimination are a lack of awareness about viral
outcomes, social stigma, global cost, treatment accessibility and adherence.
1.2. HIV-1 Structure and Life Cycle
AIDS remains a global concern foremost because there is no cure, despite
the virus being well-characterized (Figure 2). HIV is a lentivirus around 80-120 nm
in diameter with a lipid membrane surrounding its core components [12]. Within
each virion there are two viral RNA copies that code for multiple types of viral
proteins: structural polyproteins env and gag which form components relating to
the core virion and outer envelope; pol which breaks into three proteins responsible
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for vital HIV-1 enzymatic functions; gene regulatory proteins tat and rev; and
accessory proteins nef, vpr, vpu, and vif [13]. The viral RNA copies are housed
within a p24 capsid to maintain core structure. The virion membrane bilayer has
multiple glycoprotein (gp) spikes – a gp160 trimer composed of a heterodimer
exterior gp120 and transmembrane gp41 subunit. The gp120 subunit expresses
affinity for cells with CD4+ receptors, namely, primary CD4+ T cells, monocytemacrophages, and dendritic cells. Upon binding, gp120 undergoes conformational
change allowing further interaction with CXCR4 and CCR5 co-receptors. The gp41
hydrophobic subunit then fuses to the host cell, and the viral cell membrane fuses
with the host membrane to release viral contents into the host cell [14, 15]. Once
bound, the viral envelope fuses with cells to release viral contents including single
stranded RNA, viral enzymes and proteins. Virus replication begins with viral
reverse transcriptase synthesizing cDNA copies from the viral genetic RNA. This
material is translocated to the nucleus through nuclear pore channels where it
becomes integrated with the host genome, termed proviral DNA [16]. The ability
to transport into the nucleus allows HIV to replicate in terminally differentiated and
non-dividing cells such as monocytes, macrophages and dendritic cells [17]. It
remains in the cell’s genome for the duration of cell life, which is frequently less
than a week due to activation induced cell death, viral cytopathic effects, or
cytotoxic T lymphocyte (CTL) response (Figure 3, [18]). In a small percentage of
cells (approximately one in a million) through multiple proposed mechanisms, the
cells become transcriptionally dormant, resulting in ‘latent’ cells with integrated
provirus [19]. Resting HIV-1 infected T cells have half-lives several years long and
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are capable of reactivation through response to antigen or cytokine stimulation,
therefore lifelong ART is required. On a genetic level, viral dormancy or activation
is regulated both by cellular and viral transcription factors. The viral protein tat
(transactivator of transcription) is capable of stimulating cells to mass produce HIV
genetic material [20]. The RNA is then translocated outside the nucleus and
translated into various components. Assembled viral enzymes cut larger pieces
of HIV proteins ultimately assembling an immature virion. Initially virion formation
occurs with gag binding to the plasma membrane, which requires myristoylation
and phosphatidyl inositol bisphosphate [21]. The virion matures through a series
of additive events involving trafficking of various HIV-1 proteins to the budding
particle on the plasma membrane.

The mean assembly time for particles is

estimated at 10 minutes [22]. The morphological variance from flexibility of the
virion core is an example of the highly mutating nature of the virus [23]. Once a
mature virion is made it uses cellular membrane and machinery to ‘bud’ away from
the cell, whereupon it can either operate cell free or enter other cells. Viral
production typically results in cell death within a few days and production of many
virions. Cellular necrotic and apoptotic pathways are eventually activated, killing
the infected host cell.
1.3. Disease Timeline
HIV-1 is transmitted by sexual contact, exchange of infected blood by
transfusion and/or the sharing of needles, breast-feeding from an infected mother
to her newborn. The initial stage of infection is called acute infection, characterized
by CD4+ T cell counts over 500 (cells/mL of blood), and a transient spike in viral
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load. Initial clinical manifestations are relatively non-specific, with 40-90% of
patients presenting with an acute mononucleosis-like syndrome [24].

HIV is

diagnosed by HIV-1 antibody production in plasma. Many HIV infected individuals
are not aware of their infectivity, which can contribute to diagnostic problems and
inadvertent disease spread. Clinical latency occurs typically 12 weeks after viral
infection and is characterized by CD4+ T cell levels near 400 (cell/mL blood) for
most individuals. Over the remainder of disease, viral load slowly increases and
CD4+ T cell count drops, eventually reaching a critical point where opportunistic
infections begin to overwhelm the immune system, resulting in death. Clinical
symptoms associated with progression to the final disease phase, AIDS, (less than
200 CD4+ T cells/mL blood) can include opportunistic infections, Kaposi sarcoma,
dementia, recurrent pneumonia, and lymphoma among others [25].
1.4. Host Immune Response
HIV typically first encounters antigen presenting cells (APC), which engulf
it and transport it to neighboring T cells which are then believed to transport the
virus to the lymphatic and central nervous systems where active replication takes
place. The host innate responses to HIV are hypothesized to include pattern
recognition receptor (PRR) and interleukin 1 production (possibility accelerating
viral production), though the innate response is not well characterized [26].

Early

in the course of infection memory CD4+ T cells are selectively depleted. Host viral
levels are initially correlated to cytotoxic lymphocyte (CTL) response, part of the
adaptive immune response to HIV [27, 28]. Host CD8+ T cells respond to infected
CD4+ T cells in multiple ways: inhibition of viral replication via production of
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cytokines and activation of the interferon signaling pathway, prevention of viral
entry via release of competitively binding chemokines that serve as chemoattractants for lymphocytes, and release of perforin and granzyme that are
essential to cytotoxic function.

It is hypothesized depletion of interleukin-2

signaling from CD4+ to CD8+ T cells over the course of infection contributes to
loss of CD8+ response, a factor in non-treated long-term disease progression.
Single genome sequencing has been used to map evolution of viruses, indicating
viruses with abilities to escape CTL mechanisms are selectively evolved [29]. HIV
further evades CD8+ T cell responses by downregulating MHC class 1 levels on
the surface of infected cells. Continued high level antigenic stimulation coupled
with defects in CD4+ T cell function leads to CD8+ T cell exhaustion, hindering
host cellular control.

The initial robust CTL response followed by eventual

inefficacy is mirrored by the humoral immune response.

The first antibody

responses to HIV are to the envelope protein after the initial CTL response (Figure
1.3). The antibodies lose potency against virus as escape mutants selectively
evolve and multiply. B cell and CTL responses are primary components of the
adaptive immune response to HIV. Ultimately, due to a high rate of antigenic
mutation caused by substantial errors in viral enzymatic translation (viral enzymes
do not proofread, resulting in a large degree of variance, inevitably producing nonrecognizable viral epitopes to the host), and latent nonreproducing virus
sequestered predominantly in CD4+ memory T-cells, the host fails to clear
infection. Concurrent with CTL and B cell failure is a chronic immune activation,
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the persistence of which is thought to contribute to disease progression to AIDS
[30].
Notably, a small segment of people (0.5%) can suppress viremia to
undetectable levels in the absence of ART (though eventually viral load and CD4+
T cell counts become affected). Information about how this patient population is
able to control HIV is inconclusive to date [31].
1.5. Reservoir Characterization
A challenge in HIV-1 treatment and eradication is in defining the HIV-1
reservoir. The HIV-1 reservoir can be defined as latent virus that is created by ART
and not cleared by immune surveillance mechanisms. Low-level HIV-1 replication
or replication of proviral DNA as a consequence of cell division has been shown to
persist in the face of ART. This necessitates further definition of the reservoir as
containing HIV-1 that is transcriptionally silent, but replication-competent and that
could potentially replenish populations of infected cells. Generally, the reservoir is
characterized by infected long-lived memory CD4+ T cells [32]. Subtypes of
memory cells, such as effector and central, harbor different frequencies of virus in
different infected persons.

Typically, these cells have latent, non-actively

replicating virus. Other cells such as monocyte-macrophages and T follicular
helper cells harbor HIV DNA and may contribute to the overall reservoir. Lymphoid
tissues in gut, thymus, and spleen are thought to be the primary tissues harboring
latent HIV [32]. As abilities to measure HIV-1 become more sensitive, assays used
to quantitate viral reservoirs such as viral outgrowth assay (in which resting CD4+
T cells are subjected to a single round of activation with a mitogen and the resulting
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amount of virion produced is quantified [33]), may be insufficient to characterize
the reservoir. In the instance of a sterilizing treatment, the reservoir may shift
location or mutate further. The variable nature of ART, immune system, and
reservoir in treated patients makes HIV eradication strategies difficult.
1.6. HIV-1 Eradication
HIV eradication strategies have become mechanistically complex as more
agents have been discovered, entered clinical trials, and been abandoned. Cure
strategies are broadly grouped as functional (allowing virus to exist in the body but
at levels the immune system can control) or sterilizing (where virus is totally
removed from the body). To date, two HIV-infected patients have successfully
received hematopoietic stem cell treatment with a select CCR5 deletion,
successfully preventing HIV entry in hematopoietic stem cells (HSC), essentially
‘eradicating’ HIV. These patients have been off ART for over 10 years and have
not seen viral rebound. To date this result is not reproducible and extremely
invasive to patient health and immune system [34].
Several vaccine strategies have reached clinical trials, but none has
succeeded to date [35]. Given the incredible degree of HIV hypermutation, such
strategies face inherent challenges. Passive immunization strategies such as
broadly-neutralizing antibodies (bNAbs) have seen moderate success in clinics. A
small percentage of HIV infected patients naturally produce bNAbs.

This

population, combined with bNAbs produced by elite controllers (HIV infected
patients who can control viral infection naturally via host immune response, without
ARV), have been used to genetically map and therefore locate the lineage of
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endogenous host bNAbs. Immunogens were then used to stimulate B cells in
efforts to produce sequentially evolving bNAbs, in response to rapidly mutating
virus. Such sterilizing cure strategies as discussed above proposing to eliminate
virus from the body have seen limited success to date [36].
The promise of autologous modification strategies such as zinc-finger
nucleases that require complete repopulation of edited cells aim to delete coreceptor alleles in CD4+ T cells, thereby preventing entry. This technology has
been met with complications from multiple tropisms of HIV-1, need for additional
treatments (including chemotherapy), and the difficulty of personalized therapy
[37].
CRISPR (Clustered, regularly interspaced short palindromic repeats) CAS9
(a CRISPR-guided DNA exonuclease enzyme) is a DNA editing tool that can be
packaged in a lentiviral vector, an adenovirus associated vector (aav), or as a
nanoparticle. It selectively excises integrated HIV DNA from the host genome in
latent viral reservoirs. Groups have shown the ability of this system to selectively
delete the long-terminal repeat (LTR) region of HIV from specific cells [38-43].
Before gaining traction clinically, such strategies must deal with global toxicity that
can happen in non-HIV infected cells. Additionally, certain tissues in humanized
mouse models have failed to show deletion of HIV LTR, indicating lack of
penetration by CRISPR [44].
Shock and kill aims to eliminate latently infected cells in ART treated
patients by activating latent virus (shock) thus making the cells vulnerable to virusinduced cytolysis (kill) by the immune system or antibody treatment. Initial clinical
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testing of latency reversing agents (LRA) IL-2 and anti-CD3 to ART treated patients
demonstrated increased HIV replication but resulted in viral rebound upon therapy
cessation in all patients [45]. In clinical trials LRA histone deacetylase inhibitors
(HDAC) selectively reactivate cell-associated HIV RNA in resting CD+ T cells but
also do not impact latent reservoir size [46]. Other LRAs such as disulfiram, protein
kinase C (PKC) agonists, and toll-like receptor 7 (TLR-7) agonist have shown
abilities to reactivate HIV by measurement of viral RNA in blood after agent
administration [47]. Such incremental successes of immune therapy indicate a
need for further pursuance of these aims, more realistically seeking to control and
reduce virus rather than totally ablate it.
‘Kill’ agents that reactivate CTL response have not been discovered to date.
CD8 T cell control of HIV-1 will require the induction of robust, co-dominant,
broadly directed virus-specific CD8 T cell responses for an optimum vaccination
strategy. Future work is underway to resolve if CD8 T cells may need to be induced
in a manner that specifically promotes target cell recognition via MHC class 1,
class II receptors, or both [48]. Given lack of success with kill agents, a recent
study proposes to lock in HIV-1 in reactivated cells by capturing HIV-1 protein
Pr55gag to prevent virion budding. The resulting ‘locked-in’ virus then causes
cellular apoptosis [49].
1.7. HIV treatment
In February 1987, the first anti-HIV drug was released, azidothymidine
(AZT). AZT was a nucleotide reverse transcriptase inhibitor (NRTI). This class of
drug competes with endogenous cellular nucleotides (building blocks for DNA
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synthesis) for incorporation into growing DNA strands but terminates DNA chains
due to lack of a 3’ functional group on the sugar portion of the molecule. This
prevents phosphodiester linkage necessary for DNA synthesis. A common issue
with NRTIs is toxicity, which can non-specifically be used by cellular polymerases
(negatively effecting cellular DNA translation) instead of HIV reverse transcriptase
(RT). The RT crystal structure has been resolved and is used in pre-clinical
development during drug optimization [50]. NRTIs for each of the four endogenous
nucleotides have been developed.

Notable NRTIs following AZT, lamivudine

(3TC) and stavudine (d4T), were developed. This group of NRTIs were the first to
seriously improve disease outcome in patients. Development of this more potent
group of NRTIs brought to light new issues, such as the importance of basal
cellular levels of endogenous nucleotides (the equilibrium of which can be
negatively affected by NRTIs) and virus resistance (which can render a drug
ineffective against HIV).

This occurs frequently in NRTI monotherapy [51].

Common viral resistance mechanisms are believed to happen either by RT
enzymatic mutations which result in preferential incorporation of endogenous
nucleotides (instead of NRTI) by mutated RT, or an upregulation of enzymes that
dephosphorylate and continue chain elongation despite incorporation of the NRTI
into a growing DNA strand. Emtricitabine (FTC) and lamivudine (3TC) are the
widely used cytidine analogues, tenofovir (TFV) is the most widely used adenine
analogue, and abacavir (ABC) is the most widely used guanosine analogue. Of
note is a next generation NRTI translocation inhibitor, 4′-ethynyl-2-fluoro-2′deoxyadenosine (EFdA), a potent antiviral with an unusually long half-life, currently
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in phase I clinical trials. It inhibits RT through a mechanism of action different from
all approved anti-HIV drugs. After incorporation in the nascent DNA chain, it
suppresses the rate of viral replication by diminishing RT translocation on the
nucleic acid substrate. Though technically an NRTI translocation inhibitor, EFdA
represents the most potent version of NRTIs to date, with subnanomolar potency
against multiple cell types [52].
HIV-1 protease catalyzes the hydrolysis of HIV polyproteins at various
cleavage sites which produce vital viral structural proteins. The first protease
inhibitor (PI) saquinavir was developed to stop the HIV protease process. This
drug was found to be robustly metabolized by the liver enzyme CYP3A. Once viral
protease was characterized by x-ray crystallography, more potent PIs than
saquinavir were produced. PIs were initially developed to mimic the transition state
of the hydrolysis step by binding with catalytic aspartic acid on HIV protease. PIs
often had structural similarities to small peptides and therefore had high metabolic
clearance (often from liver cytochrome P450 3A enzymes, termed CYP3A, poor
half-life and poor oral bioavailability. Side effects such as nausea and diarrhea
were problematic. The decade from 1997-2007 saw development of more potent
PIs with improved safety and tolerability. Darunivar, tipranavir, and atazanavir, all
exhibit improved potency and better resistance profiles and are currently FDA
approved.
Non-nucleoside reverse transcriptase inhibitors (NNRTI) were initially
developed alongside PIs, namely nevirapine, delavirdine, and efavirenz. NNRTI
bind to pockets outside of RT, causing conformational changes near the active

13
site. NNRTI are therefore also susceptible to resistance mechanisms in the form
of RT mutation. Recently the FDA approved NNRTI rilpiverine has been included
in the first studies of long-acting ART, exhibiting non-inferiority when coadministered with cabotegravir against a 3 oral pill regimen [53]
Studies using highly effective ART (HAART) were first published in 1995
and 1996 and showed sustained HIV suppression (<400 copies/mL) for the
duration of the study [17]. HAART regimens consisted of two NRTIs plus a PI or
NNRTI. Widespread use quickly led to reduction in mortality in the developing
world. The strategy of using two NRTIs plus a third agent still forms a cornerstone
of ART. The importance of measuring viral load as a predictive risk of disease
progression was first realized in these combination therapy studies [54].

The

ability to measure lower level viremia (<40 copies per ml-1) led to the realization
that virologic suppression was incomplete, and treatment breaks in HAART were
deleterious.
New classes of drugs continue to emerge, improving treatment options after
landmark combination ART (cART) studies in the middle 1990s. Enfuvirtide, a
fusion inhibitor, was approved by the FDA and inhibits HIV viral entry into cells. It
competitively binds to the hairpin region within the hydrophobic pocket of gp41
subunit after the gp160 envelope undergoes conformational changes before
entering the cell. Importantly, this drug cannot be given orally, and has a short
acting half-life, preventing widespread market use [55]. Along with maraviroc, it is
one of two approved FDA entry inhibitors. Maraviroc acts by blocking HIV fusion
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with CCR5 after GP120 undergoes conformational change allowing virion binding
with the co-receptor.
The first integrase strand transfer inhibitor (INSTI) raltegravir was
developed in 2007, selectively blocking the strand transfer reaction catalyzed by
HIV integrase (IN), preventing formation of immature virions after translation [56].
After nuclear translocation, IN associates with lens epithelium-derived growth
factor (LEDGF)/p75 and is directed to sites of open chromatin, where it will initiate
strand transfer, i.e. the nucleophilic attack of the 3′ hydroxyl groups on the viral
DNA on the nucleotide backbone of the host DNA. The integration process is
completed by host gap-repair machinery, resulting in a 5 base-pair repeat that
flanks each end of the viral DNA. INSTIs stop this by chelating the divalent cation
(Mg2+ or Mn2+) that is required for IN enzymatic activity [57]. There are currently
several INSTIs approved for the treatment of HIV infection, including raltegravir
(RAL), elvitegravir (EVG), and dolutegravir (DTG). New potent INSTIs are in
clinical trials (Figure 1.5).
Most recently, the integrase inhibitor dolutegravir combined with tenofovir
disoproxil and emtricitabine is a standard first line of care (Figure 1.4). Globally,
3TC and abacavir alongside atazanavir are the most affordable treatment options.
Though ART therapy continues to decrease pill burden, most treatment options
are single pill daily regimens. Within the last few years, long-acting version of
formulated drugs, namely long-acting (LA) rilpiverine (RPV) and LA cabotegravir
(CAB) are emerging as alternatives to oral medicine. Currently in phase 3 trials as
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every 2-month injectables, given intramuscularly (IM), these formulations
demonstrated non-inferiority to 3TC/ABC/CAB regimen in the LATTE 2 trial [53].
1.8. Long Acting Nanomedicine for Antiretroviral Therapy
Nanomedicine, specifically nanoparticle-based therapeutics, is a relatively
new branch of science, capable of addressing many previously unmet needs in
HIV treatment and prevention. Nanomedicines typically contain crystalline drug
particles nanometer range (1nm-1000nm). Nanoformulations are the process of
developing particle nanomedicine. Over the last decade our lab and others has
evolved the field of nanomedicine using formulation techniques capable of
imparting substantial benefit in the fields of HIV, theranostics, Parkinson’s disease,
cancer, and Alzheimer’s disease [58-69]. The term ‘nano-ART’ originally coined
by the Gendelman laboratory, is characterized by usage of hydrophobic ARV drugs
coated with biodegradable surfactants in the nanosized range with an ability to
target immune cells [70]. These nanosized particles typically contain high drug
encasement, simplicity, scalability, and ability to tailor delivery sites via surfactant
modification. Nanoformulation preparation frequently uses top down approaches
such as wet-milling and high-pressure homogenization to achieve desired particle
size [71]. Of note, different drugs produce different sized particles. Size, shape,
and zeta potential play a role with each individual drug in determining its uptake
into various cells [67, 72]. This transfer be partially seen through in vitro models
using human brain microvascular endothelial cells to facilitate transfer [73]. Drug
uptake is further influenced by surfactant selection.

Typical formulations of

nanosized particles are frequently coated with surfactants such as polymers and
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lipids [74]. Folic-acid coated poloxamer 407 coated nano-art increased atazanavir
drug uptake as compared non-targeted nanoformulation [63, 75]. Nano-ART has
demonstrated improved drug pharmacokinetics and pharmacodynamics as
compared to ART [76-78]. An additional benefit from nanoformulations is their
improved uptake in macrophages [68]. Macrophages can serve as trojan horses
to deliver crystalline forms for drug, including viral sanctuaries such as the blood
brain barrier [80]. Cell based drug delivery systems using indinavir (IDV) were
shown to exhibit improved abilities to deliver drug to brain [79, 80].

Further,

subcellular trafficking enhances the antiretroviral drug response in nano-ART
systems [81].

Autophagy in these cells can stimulate sustained release for

nanoformulated drugs [82].
Tens of nanoparticle-based therapeutics have entered clinical trials in the
last 15 years and are increasingly being explored for therapeutic application [83].
Many accounts demonstrate the potential of nanotechnology-based drug delivery
systems, by enhanced cellular drug uptake, improved potency, abilities to target
specific cells and tissues thereby improving pharmacokinetics.

When an

antiretroviral drug is encapsulated into a nanosystem, its absorption, metabolism
and excretion are not exclusively governed by drug properties but also the
formulation properties, particularly surface-exposed molecules, electric charge,
size, and shape. Drug particles being formulated must exhibit physiochemical
properties that allow distribution and localization of drug particles within the sites
of interest, while minimizing peripheral toxicity [84]. Nanomedicines are tunable
and can be formulated in many classical ways (Figure 1.6).
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1.8.1. Liposomes
Liposomes are closed phospholipid bilayer vesicular systems, capable of
incorporating both water soluble and water insoluble drugs at the same time.
Liposomes can also have attached targeting moieties to confer benefit of reaching
particular cells or tissues [85]. Injected liposomes typically avoid uptake by the
reticuloendothelial system (RES) by being less than 200nm and circulate for longer
periods of time than typical medicines. Liposomes are repeatedly passed through
filters to control their size. Approximately 15 liposomal formulations have market
approval and can be made long-acting through technologies such as: StealthLiposome Technology, Non-pegylated technology, and Lysolipid Thermally
Sensitive Technology [86].
1.8.2. Micelles
Chemicals which have an amphiphilic nature (hydrophilic and hydrophobic
portions) inherently have the capacity to form micelles in aqueous solution.
Micelles are generated when the hydrophobic portions are driven to an interior
structure while hydrophilic portions are turned outward facing toward the water.
Common applications of this technology use a variety of surfactants (surface active
agents), detergents, soaps, lubricants and others [87]. Polymer micelles can be
used for drug delivery as the hydrophobic interior has the capacity to hold drugs
which are poorly soluble in aqueous solution [88]. When placed in water, the total
molecular weight (MW) of the polymer as well as which polymer chain block is
larger dictates micelle formation. Micelles form only when the concentration of
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surfactant is greater than the critical micelle concentration (CMC) and the
temperature of the system is greater than the critical micelle temperature [89].
1.8.3. Polymer-Chemo Conjugates
The

covalent

conjugation

of

synthetic

polymers

such

as

poly(ethyleneglycol) (PEG) to protein drugs increases their water solubility. This
can result in increased plasma residence time, reduced protein immunogenicity
and overall improved therapeutic index [90].

Water-soluble polymers conjugated

to proteins and anticancer drugs are in routine clinical use as chemotherapeutic
agents and other cancer therapies [91]. Drug-polymer conjugates increase halflife and bioavailability, and are one of two broadly defined polymeric nanoparticle
types, the other consisting of degradable polymers encasing drug [92].
1.8.4. Solid Lipid Nanoparticles (SLN)
SLNs are sub-micron dispersion systems composed of physiological lipids
which consolidate to form SLNs in aqueous surfactant solutions. SLNs offer unique
properties such as miniature size with large surface area, high drug-loading
capacity and extended drug-release profile due to slow degradation lipid matrix
composition [93]. SLNs protect and prevent the drug molecule from degradation.
SLNs are typically administered for transdermal delivery, and offer sustained
release while minimizing drug toxicity, dosing frequency, and ﬂuctuation in plasma
drug concentration [94]. Drug-release kinetics from SLNs are typically biphasic
and are affected by melting point of lipids and drug deposition pattern [95].
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1.8.5. Niosomes
Niosomes are nonionic surfactant vesicles that can form unilamellar and
multilamellar vesicles which have properties similar to liposomes. They can encase
a variety of drugs. Niosomes have been tested with AZT and shown to accumulate
in tissues with high macrophage levels after topical or IV injection [96]. Niosomes
can alter the biodistribution to provide a greater degree of targeting of the drug to
tissues and are a low-cost alternative to liposomes [97].
1.8.6. Nanosuspensions
Though many additional formulation methods exist and have been used to
formulate long-acting HIV medicines, perhaps the most clinically promising
nanomedicines are nanosuspensions. Nanosuspensions are aqueous colloidal
suspensions containing drug crystals typically around 100–200 nm. The aqueous
media is often a buffer to maintain constant pH, and the colloidal particles are
coated with surfactant to prevent crystal growth and aggregation [98]. They are
classically used to facilitate oral absorption of Biopharmaceutics Classification
System (BCS) class II and IV compounds, which are frequently produced with high
throughput screening [99]. Their ability to increase the active pharmaceutical
ingredient (API) dissolution rate and subsequent absorption and thus oral
bioavailability has been demonstrated in preclinical and clinical settings [5, 6, 53,
63, 67, 100-104]. The saturation solubility of the nanocrystals is highly related to
the particle size, and solubility increases with particle size decrease due to the
increased surface area, especially when the nanocrystals are below 300 nm.
1.8.7. Nanoparticle Systems and Characterization
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Particle size is a relevant parameter for dosing, and highly relevant for the
pharmacokinetics of a drug. Drugs greater than 100nm have difficultly crossing
the blood-brain barrier (BBB), while particles greater than 200nm can more easily
be recognized by the reticuloendothelial system (RES).

On a cellular level,

nanoparticles typically enter cells through passive diffusion, endocytosis, or
phagocytosis [72]. Particle size in nanosuspensions is determined by
physicochemical properties of the API, polymer/surfactants used, formulation
technique, and amount of drug and surfactant used. Particle size also determines
circulation time and route of metabolism (i.e. liver or kidney) and is typically
characterized by dynamic light scattering (DLS). Particles are dispersed in a
solvent and interact with solvent atoms. DLS measures Brownian motion and
relates this to particle size [105]. Nanoparticles can also be fixed and measured
via scanning electron microscopy (SEM), transmission electron microscopy (TEM),
or NanoSight technology [106] .
Nanoparticles are further characterized by electrokinetic potential, or zeta
potential. Dispersed charged particles develop adsorbed double layers on its
surface. The composition of this layer is dynamic, and changes when an electric
field is applied. Ultimately, zeta potential is a predictor of particle stability, and can
be predictive of how the particles will interact in a cellular environment with an
immune system. A high positive or negative charge indicates particles will repel
each other, not aggregate, and exhibit stability [107, 108]. pH has a substantial
impact on zeta potential and must be considered when choosing a buffer system.
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Polydispersity (PDI) as determined by DLS is unitless and characterizes the
variance in particle size. A value of 1 indicates different sizes of all particles, while
a value of zero indicates all particles are the same size. Values greater than 0.4
are generally varied in size to cause non-predictable behavior in a biological
system. The lower the pdi, the more stable the suspension will likely be as particles
will be less likely to sediment [109].
Nanoparticle systems are characterized by encapsulation efficiency (EE)
and drug loading.

EE refers to the amount of drug encapsulated in the

nanoparticles relative to the total amount of drug added, while drug loading refers
to the amount of drug encapsulated in the nanoparticle relative to the amount of
excipient.
1.9. Nanoparticle Preparation
A multitude of nanoparticle preparation methods exist and will not be
discussed at length. Formulations are often made via a top-down or bottom-up
approach [99]. Top-down approaches break larger micro-sized particles down,
such as wet-milling or high-pressure homogenization (HPH) [110]. HPH is a
mechanical process that forces a fluidic product through a narrow gap (the
homogenizing nozzle) at high pressure. Bottom-up approaches build particles up
from the molecular state, such as precipitation [111]. A new surface area is formed
in all cases. Formulation approaches can affect size and shape of the nanoparticle
and are often taken into consideration when addressing problems with
nanoparticle stability and type of excipients to be used.
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1.10. Studying Antiviral Activity in Murine Mouse Models
In the case of HIV-1, multiple well-established cell culture methods exist in
monocyte-derived macrophages, dendritic cells, and many different CD4+ primary
and non-primary T cell lines [112-114]. Consideration of preclinical testing in
biological systems for HIV is inherently difficult, as the most common non-human
model used to study disease – mice - do not respond to HIV, and the virus injected
alone is cleared quickly from the blood [115]. Chimeric HIV strains ecoHIV and
SHIV have allowed study of HIV in mouse and non-human primates (NHP),
respectively [116-118]. The ecoHIV strain is substantially different from HIV, with
the gp120 protein replaced by gp80 [119]. SHIV is often used just before clinical
trials, is expensive, and suited for testing close to clinical stages. For earlier
preclinical work, humanized mice accurately replicate HIV disease pathology in
many

ways

and

offer

a

more

accessible

way

to

study formulation

pharmacodynamics [120]. Humanized mice refer to transplanting human cells into
mice to allow for HIV susceptibility.
Early studies in HIV humanized used mice homozygous for the NOD-SCID
mouse strain, resulting in severely depleted mouse B, T, and NK cell populations
[121-123]. The SCID mutation essentially prevents mouse adaptive immunity by
knocking out the PRKDC gene. NK populations can be inhibited by injection of rat
anti CD122 antibody in this model [124]. This model is frequently used for acute
infection studies. When injected with peripheral blood lymphocytes (PBL) from
human donors, mice become substantially repopulated with human T cells.
Cellular and humoral immune responses can be recapitulated in such models [122,
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123, 125, 126]. Interleukin-2 receptor gamma chain knockout provided additional
model options. The IL-2 chain knockout further prevents NK cells from inhibiting
human hematopoietic stem cell reconstitution [121]

Additional HIV-1 mouse

models reconstitute mice through CD34+ hematopoietic stem cell engraftment.
[127]. Another acceptable model to measure HIV-1 reconstitution is bone marrow
liver thymus (BLT) transplant mice (Figure 1.7). Human fetal liver and tissue are
transplanted into immunodeficient mice, and subsequent HIV infection accurately
mimics human immune reconstitution and HIV-1 responses [128]. These mouse
models

showed

an

ability

to

distinctively

activate

and

mobilize human plasmacytoid dendritic cells (pDCs), myeloid DCs (mDCs) and
monocytes in different organs. This is correlated with antigen specific CD8+
immune response [126, 129, 130]. Additional aspects of HIV disease progression
these mouse models - especially the BLT and hematopoietic stem cell transplant
models - accurately mimic is viral mutation, latency, and response of ART[131134]. Furthermore, cellular HIV-1 DNA levels have been associated with disease
progression. Common issues present in most cellular mouse models are eventual
graft versus host disease and consistency in HIV-1 infection reconstitution.
1.11. Scope and Significance of the Works Presented
The studies presented herein aim to advance prodrug development and
subsequent nanoformulation of small molecule inhibitors primary for not only HIV1 infection, but to examine broad-spectrum antiviral activity when applicable. This
approach intends to create more lipophilic, hydrophobic versions of antivirals or
immune modulators, resulting in higher encapsulation efficiency for their
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subsequent nanosuspension.

These nanosuspensions can allow for higher

cellular penetration and improved drug efficacy with eventual translation as
parenteral injections in PK and BD studies. This work is in part an expansion of
previous works with long-acting slow effective release (LASER) antiretroviral
therapy that has seen measurable success of similar application to a range of
antiretroviral drugs [6, 63, 75, 100, 101, 103, 104]. The potential improvements to
drug combinations include those seen in the recent LA-RPV and LA-CAB. In the
case of the formulations used in the LATTE trial, parenteral injection of
nanoformulations allows a small non-toxic depot to form near the injection site,
permitting enough release of the drug over time to be effective, but not so much
as to be quickly metabolized and excreted.
Herein, three individual small molecules will be tested separately; two within
the context of antiviral treatment, and one within the context of an HIV-1 cure.
Generation of nanoformulation libraries have inherent value, with each drug
possessing a different, often undefined ultimate role in disease context. Therefore,
development of each drug will be treated separately.
In these works, prodrugs will be used. Prodrugs are defined as a compound
that is converted into the active form of a drug after metabolic or enzymatic
conversion. Prodrugs are a well-established technology in scientific literature, and
particular prodrug construction of each compound will vary [135].
Each study operates under the paradigm of long-acting formulations to
avoid pitfalls frequently found in oral administration. This will initially be considered
during prodrug construction. Prodrugs will be well characterized by NMR and FTIR
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in addition to cytotoxicity and potency. Prodrugs will subsequently be encased in
nanoformulation using varying surfactants, with an emphasis placed on particle
size, charge, and stability. The final common denominator of these projects is in
their usage of macrophage cell culture systems to characterize nanoparticles.
Given that the nanosuspension-poloxamer encasement system frequently imparts
a substantial charge on the molecule, electrostatic attraction between nanoparticle
and macrophage can potentially drive phagocytosis. Once in the cytoplasm of the
macrophage, endosomal compartments have been shown to have great carrying
capacity [81, 82]. A potential mechanism for drug delivery to viral sanctuaries
might be through macrophage-mediated delivery by slow release of the prodrug at
sites of interest [84]. All projects will aim to improve drug uptake into macrophages.
Given the difficulty in HIV-1 eradication to date and the complexities of the
immune system, administration of a single small molecule inhibitor will most
certainly not cure HIV. Given advances in mouse models and prior studies, the
indoleamine 2,3-dioxygenase (IDO) enzyme may be part of the complex interplay
between immune system and HIV that can be fine-tuned to host advantage [136].
One aim of the IDO project is to utilize a new isotype-specific enzyme inhibitor to
examine a relationship between tissue specific and body wide inhibition of IDO-1
with HIV-1 viral load. Opportunities to examine T cell phenotype and associate
other biomarkers in this disease context may contribute to the role of IDO in HIV.
Both NRTI projects (tenofovir and lamivudine) involve hydrophilic shortacting drugs. Attempts to improve drug potency and bioavailability have been
hugely successful with tenofovir, with Gilead producing an FDA prodrug tenofovir
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alafenamide in 2015 [137]. 3TC has remained the same for 20 years [138]. Both
projects will seek to revise older base compounds using established medicinal
chemistry technology to develop as long acting nanoformulations. Success or
failure of this platformed approach will be evaluated on a drug by drug basis.
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Figure 1.1: Adult HIV prevalence, 2017.
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Figure 1.2: HIV-1 Virion life cycle (Adapted from Mehta, et al., Cureus. 2017;9(3):e1093.
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Figure 1.3: Innate and adaptive host response to HIV-1. Adopted from British Society for
Immunology. https://www.immunology.org/public-information/bitesized-immunology/pathogensand-disease/human-immunodeficiency-virus-hiv
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Figure 1.4: A putative mechanism of HIV-1 latency: Activation of resting cells by antigen upregulation
of CCR5 expression and reversing other blocks to HIV-1 replication in resting CD4+ T cells, allowing
productive infection of resting cells. Adapted from: Murray, A. et. Al. J Immunol 2016; 197:407-417

31

Figure 1.5: FDA-approved antiretroviral drugs and combinations. Adapted from Cihlar
et al. Current Opinion in Virology. 50-56, V. 18 (2016)
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Figure 1.6: Various Nanotechnology platforms used in HIV treatment and
prevention. Adapted from Mamo, T. et al. Nanomedicine (Lond). 2010 Feb;
5(2): 269–285
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Figure 1.7: Biom, B. et al. Humanized Mouse Models for HIV. DOI: 10.5772/21588
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Chapter 2

Project Hypotheses and Goals
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2.1. Hypotheses and Aims
Project 1: IDO inhibitor (Chapter 3)

We hypothesize that pharmacological inhibition of IDO-1 can facilitate host
cellular immune response to HIV-1 and accelerate its elimination. We predict that
macrophage targeted drug delivery through nanoformulation of a next generation
IDO inhibitor will increase HIV-1 clearance.

The scientific importance of this

system would be best realized in preclinical HIV-1 mouse models. Thus, we
propose the following specific aims.
Aim 1:
We will develop and characterize pro-drugs of IDO inhibitors in order to
optimize their loading capacity and carriage within nanoparticles. We will evaluate
its size, charge and polydispersity and substantiate its structure and functional
properties by proton nuclear magnetic resonance spectroscopy (1H-NMR). We will
decorate the polymer used with targeting ligands based on what is operative in the
laboratory to facilitate its entry into monocyte-macrophages acting as cell depots
and drug distributors. We will evaluate toxicology profiles of the new developed
formulations and test the degradation of the essential amino acid L-tryptophan to
N-formylkynurenine

in

primary

monocyte-macrophages

and

in

replicate

lipopolysaccharide (LPS) active cells.
Aim 2:
We will evaluate the pharmacokinetic (PK) profiles for the aim 1 developed
nanosuspension in normal mice and rats. This will be done through direct drug
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measurements and by assays of the conversion of L-tryptophan to L-kynurenine
in mice. Replicate assays of tissues will be explored in vivo.
Aim 3:
We will test the antiretroviral activities of the developed IDO inhibitor drug
nanoparticles in humanized mice. We will examine the effects of the IDO
inhibitor(s) developed in aims 1 and 2 for their abilities to reduce residual virus at
tissue sites for viral infection in bone marrow, blood, spleens, liver, gut, brain,
kidney and lungs.

Lastly, evaluation of links between HIV and IDO will be

examined by examination of tissue specific metabolites and T cell phenotypes.
Projects 2 and 3: Long-Acting NRTI ProTides (Chapters 4 and 5)

We hypothesize that creating lipophilic, hydrophobic ProTide libraries of
NRTI prodrugs, specifically lamivudine (3TC) and tenofovir (TFV) will generate
“potent” long acting slow effective release antiretroviral therapy (LASER ART). We
hypothesize that TFV and 3TC can be made as single long-lasting parenteral
nanoformulations with increased cellular permeability, extended capacity for nontoxic hibernation within phagocytic cells, and increased antiviral efficacy.
Initial aims (Chapters 4 and 5)
Creation of TFV and 3TC prodrug nanoformulations may improve particle
stability, extend the drug’s apparent half-life and achieve “best” antiretroviral
potency. ProTide technology will be used to construct a library of compounds for
3TC and TFV. To ensure proper hydrolysis, the aryl motif will remain constant.
Lipophilic aliphatic residues will be combined and substituted with the amino acid
motif to confer additional hydrophobicity and lipophilicity to the constructed
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prodrugs in order to promote stability for the nanoformulations.

Each drug

formulation will be categorized by hydrophobicity, lipophilicity, and antiretroviral
activity. The resultant chemically stable and antiretroviral “effective” prodrug will
be formulated by top-down high-pressure homogenization at physiological pH.
Nanoformulations stable for a minimum of 30 days in suspension will be
administered to cell cultures and evaluated for short-term cell-nanoparticle
interaction.
Secondary aims (Chapter 5)
Compound efficacy against HIV will be evaluated in primary human
monocytes and CD4+ T cell cultures. Viral infection will be monitored in the treated
cells and HIV-1 challenged cell over a thirty-day time period. Formulation integrity
and activity will be investigated primarily by measurement of intracellular 3TC
triphosphate (3TC-TP) and by viral activity assays measured by p24 staining and
RT activity. Formulations will be characterized before and after use in cell systems
by size, zeta potential, pdi, drug release rate and stability.
Tertiary aim (Chapter 5)
Evaluation of pharmacokinetic (PK) and biodistribution (BD) profiles of the
3TC nanoformulations developed in aim 1 in rodent models. PK and BD for 3TC
protides will be assessed based on single dose injection at 75 mg/kg in mice and
rats over a time period of one month. 3TC and 3TC-TP, in plasma, gut, lymph
node, liver, spleen, kidney, and brain will be measured. The measured drug
concentrations will generate PK profiles such as bioavailability and depot release
rates for each of the formulations developed in aim 1. Intracellular triphosphate
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levels in blood and tissues of interest (PBMCs, lymph nodes, and spleen) will be
evaluated.
Quaternary aim (Chapter 6): NM23TC testing against Hepatitis B in Humanized Mice

Testing of 3TC monotherapy for pre-exposure prophylaxis treatments
using humanized mice has proven ineffectual in mice and humans. Therefore, to
test the effectiveness of a single, long-lasting parenteral injection, the antiviral
abilities of 3TC will be tested against another disease in which it is a first-line
treatment for chronic illness, hepatitis B (HBV). TK-NOG mice will be transplanted
with human hepatocytes intrasplenically, a model capable of recapitulating
biphasic aspects of HBV disease progression. Human albumin and hepatitis B
surface antigen (HBsAg) will be measured in peripheral blood.

Following

confirmation of HBV DNA in peripheral blood, animals will be administered a single
intramuscular dose of 75 mg/kg 3TC equivalents of NM23TC and control kept
without drug. Levels of HBV DNA and HBsAg in plasma will be monitored over the
2 - 8-week experiment duration. At the end of the study, liver and tissues will be
analyzed for drug concentration, HBV DNA and RNA by RT-PCR, and antibody
staining for human cells and viral proteins.
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Chapter 3

Development and testing of a nanoformulated IDO
inhibitor for HIV Eradication.
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3.1. Abstract.
The aim of this work was to prolong apparent half-life of a short-acting small
molecule indoleamine 2’3’-dideoxygenase (IDO) inhibitor (IDOi) – originally
intended for tumor treatments - in rodents and evaluate its abilities to inhibit HIV in
humanized mice. A next-generation IDOi specific to IDO-1, termed epacadostat,
was modified via the functional hydroxyl group via one step chemical synthesis to
add a 14-carbon chain fatty acid, creating a more hydrophobic iteration (M1epacadostat).

Nanoformulation of the prodrug with folic acid conjugated

poloxamer 407 (P407) maintained drug potency and was characterized in MDM
over a short period. Single IM injection in PK studies produced plasma drug levels
5 times higher than either oral gavage or IM injection of the compound as
administered by the collaborator and developer of the original compound
(GlaxoSmithKline). Prodrug tissue levels were also substantially higher in muscle,
spleen, and liver, in folate-deficient Balb/C mice after 24 hours. This correlated
with a global decrease in kynurenine after 24 hours. When treated in PBLhumanized mice, no differences were observed in kynurenine or tryptophan levels
in plasma or tissue in control groups vs IDOi treated groups. When tested in PBL
reconstituted humanized mice, HIV-1 disease progression as measured by viral
load, CD4+ and CD8+ T cells was not altered through formulation.
3.2. Introduction.
Indoleamine 2,3-dioxygenase (IDO) is the cytoplasmic rate-limiting enzyme
of

tryptophan

catabolism

transcriptionally

induced

by

IFN-gamma

and

predominantly expressed in antigen-presenting cells (APCs). IDO inhibitors (IDOi)
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are classically considered for use in cancer treatments. They affect the behavior
of neighboring T cells through tryptophan depletion or kynurenine and metabolite
production. Also viewed as potential ‘kill’ agents in shock and kill HIV eradication
strategies, IDOi are intricately linked with HIV [139]. IDO is an immune mediator
in HIV pathogenesis. The major catabolic pathway of tryptophan is through IDO,
producing kynurenine and other downstream metabolites associated with HIV-1
disease progression. Higher IDO activity (as defined by ratio of plasma kynurenine
to tryptophan) is associated with lower CD4+ T cell counts and higher plasma
sCD14 levels in HIV infected patients [140].

IDO overexpression in vitro impairs

CD4+ and CD8+ T cell function [141]. HIV-1 viral proteins such as tat upregulate
IDO in human monocyte derived-dendritic cells, causing reduced capacity to
stimulate T cell proliferation, an effect directly reversed by 1-methyl tryptophan (1MT), a first generation IDO inhibitor.

IDO is implicated in HIV persistence,

progression and anergic CD8+ T cell function [140, 142-144]. HAART decreases
IDO activity, but the enzyme and its metabolites remain elevated in HIV-1 patients
[145].

The pharmacological small molecule inhibitor 1-MT reverses local

phenotypic immunomodulatory IDO induced T-cell changes [140]. Experimental
work showed 1-MT treatment in HIV infected animals increased numbers of human
CD8+/IFN-gamma T cells and HIV-1 gag/pol specific CTLs in the periphery
combined with an increased CD8+ localization with HIV-1 infected cells [146].
Therefore, IDO pharmacological inhibition can prompt CTL response in a lentiviral
context. Two small scale non-human primate studies directly examined 1-MT
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impact on ART-treated macaques [147, 148]. IDOi synergism with ART in
decreasing viral load was observed.
Despite encouraging results from NHP and rodent studies, several key
observations made warrant further investigation of IDOi.

First, IDOi was

hypothesized to synergize with ART, either through reduction of systemic
inflammation, alteration of T cell proliferation and differentiation, or induction of a
‘kill’ type immune response [148]. This synergy was seen through a decrease in
viral load, not through an ability to prolong viral rebound when animals went off
treatment (as would be expected from a ‘kill’ agent). The first generation IDOi used
in the study, 1-methyl tryptophan, was also shown in control groups to increase
IDO and TGF-beta mRNA expression indicating induction of counterregulatory
mechanisms by d-1MT. This was complemented by insufficient viral reduction in
tissues through ART, inappropriate ART regimens causing toxicity in several
primates, and lack of tissue level correlates to viral rebound. Future IDOi work in
HIV-1 should address these deficiencies.
The most frequently used IDOi in literature is 1-MT, a racemic mixture of 1D-MT and 1-L-MT. Mechanistic studies show 1-MT does not directly inhibit IDO1, and therefore cannot answer the question of whether direct IDO1 enzyme
blockade can produce a therapeutic effect [149]. This does not invalidate previous
findings of 1-MT, as other IDO enzymes utilize a similar pathway. Yet IDO-1 is the
most characterized of the 3 IDO isoforms in humans, and most associated with
immunomodulatory effects. Given that IDO-1 specific IDOi given orally, are BCS
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class 2 or 4, and optimized for tumors, focused delivery to IDO-1 expressing tissue
(i.e. spleen, gut, lymph) and cells may be gained through targeted formulation.
Epacadostat is a next-generation IDOi developed originally by Incyte and
GlaxoSmithKline. It exhibits selective nanomolar potency of IDO in HeLa cells.
Testing in mice revealed epacadostat pharmacodynamic inhibits IDO, as
measured by kynurenine levels in plasma and reduction in tumor volume in tumorbearing mice [150]. Dosed twice daily in macaques in a 20% captisol/water
solution at 600mg twice daily 50% IDO inhibition in plasma was observed.
Currently, epacadostat is in 2 phase 1 clinical trials with immune checkpoint
inhibitors for treatment of tumor growth in cancer. Orally formulated epacadostat
has a terminal half-life of 2 hours in mice. It is 10,000 times more potent in vitro
than 1-MT. Despite mixed results in tumor studies of the stand-alone efficacy of
epacadostat, it remains the most potent IDO-1 inhibitor made to date [151].
Macrophages, alongside other APCs, play an important role in maintaining
peripheral immune tolerance.

MDMs have been shown to suppress T cell

proliferation through rapid tryptophan depletion [152]. Macrophages can act as
drug-delivery vehicles, with the ability to penetrate the blood-brain barrier and
widely distribute drug in tissue.

Nanoparticles will allow for the most potent

realization of this potential through several distinct advantages over their free drug
counterparts: encapsulation of drug preventing enzymatic degradation, the use of
tissue targeting via specific ligands, and controlled drug release. Screening of
multiple targeting ligands previously in our lab identified several candidates likely
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to improve macrophage-specific uptake (folic acid, mannose, and hyaluronic acid
among others).
3.3. Materials and Methods
3.3.1. Chemicals and Reagents
Epacadostat was purchased from Boc sciences (New York, New York,
USA). Poloxamer 407 (P407) and chemical reagents were obtained from SigmaAldrich (St. Louis, MO, USA). Pooled human serum was obtained from
Innovative Biologics (herndon, VA, USA). Macrophage colony stimulating factor
(MCSF) was prepared from 5/9m alpha 3-18 cells (ATCC, CRL-10154TM)
cultured in ATCC complete growth medium as described.
3.3.2. Synthesis and Characterization of Epacadostat Prodrugs
3.3.2.1. Synthesis of M1-Epacadostat
Epacadostat (1.4g, 3.22mmol) was dried azeotropically from anhydrous
pyridine (2mL), resuspended in 15 mL tetrahydrofuran (THF) cooled to -78°C,
followed by addition of tBuMgCl (0.606mL, 4.83 mmol) and allowed to stir for 15
minutes under an argon atmosphere. To this mixture, 1.05mL myristoyl chloride
(3.864mmol) was added drop-wise over 10 minutes. The reaction mixture was
gradually warmed to room temperature and stirred for 48 hours after which M1epacadostat was obtained (Figure 3.1 A). The mixture was then quenched with
10 mL methanol, and separated by flash chromatography using 1:1 ethyl
acetate:hexane mixture. Flash chromatography was performed using 32-63 μm
flash silica gels from SiliiCycle Inc. Reactions were monitored by thin-layered

45
chromatography (TLC) on precoated silica plates. The compounds were
visualized using UV fluorescence. Following purification, the compound was
extracted using washes of ethyl ether (25mL), with centrifugal spin-down after
each wash at 1000 x g. This was repeated twice, collecting the pellet each time.
The resultant product was white in color with a yield ranging from 20-50%.
3.3.2.2. Synthesis of M2-Epacadostat
Epacadostat (1.4g, 3.22mmol) was dried azeotropically from anhydrous
pyridine (2mL), resuspended in 15 mL THF, cooled to -78°C, followed by addition
of tBuMgCl (4.83 mmol) and allowed to stir for 15 minutes under an argon
atmosphere. To this mixture, 1.26mL oleic acid (3.864 mmol) was added drop
wise over 10 minutes.

The reaction mixture was gradually warmed to room

temperature and stirred for 48 hours after which a crude product was obtained.
The mixture was then quenched with 10 mL methanol, and separated by flash
chromatography using 1:1 ethyl acetate:hexane mixture. Following purification,
the compound was extracted using washes of ethyl ether (25mL). The resultant
product was a yellowish gel.
3.3.2.3. Synthesis of M3-Epacadostat
Epacadostat (1.4g, 3.22 mmol) was dried azeotropically from anhydrous
pyridine (2mL), resuspended in 5mL pyridine and added to N-hydroxysuccinimide
(3.84 mmol) and dimethylaminopyridine (3.84 mmol) and alpha-tocopherol and
allowed to stir at room temperature for 1 day. The resulting product was then
separated using flash chromatography.

The purified product was then

resuspended in THF (10mL), cooled to -78°C, followed by addition of tBuMgCl
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(4.83 mmol) and allowed to stir for 15 minutes under an argon atmosphere. The
reaction mixture was run for 2 days gradually warming to room temperature. The
reaction was quenched in methanol and purified with flash chromatography. The
resulting product was a yellowish gel.
3.3.2.4. Synthesis of M4-Epacadostat
Epacadostat (1.4g, 3.22mmol) was dried azeotropically from anhydrous
pyridine (2mL), resuspended in 15 mL THF, cooled to -78°C, followed by addition
of tBuMgCl (0.606mL, 4.83 mmol) and allowed to stir for 15 minutes under an argon
atmosphere. To this mixture, 0.50mL Benzoyl chloride (3.864 mmol) was added
drop wise. The reaction mixture was gradually warmed to room temperature and
stirred for 48 hours after which M4-epacadostat was obtained. The reaction was
stopped with 1mL of 1M saturated sodium hydroxide (NaCl). The mixture was then
quenched with 10 mL methanol, and separated by flash chromatography using 1:1
ethyl acetate:hexane mixture. The resulting product was a yellowish gel.
3.3.2.5. Prodrug Physicochemical Characterization
1H-NMR

spectra were recorded on a Varian Unity/Inova-500NB (500 MHz;

Varian Medical Systems Inc., Palo Alto, CA, USA). Mass was determined on a on
a Waters TQS Micro (Waters, Milford, MA) mass spectrometer. Ninhydrin staining
was performed on TLC silica coated plates to confirm stereospecific addition to the
hydroxyl group. Only compounds forming a solid powder and confirmed via 1HNMR and mass spectrometry were advanced for further characterization.
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3.3.2.6. Solubility in Water, Ethyl Acetate, Chloroform, and
Dichloromethane
Solubilities of epacadostat and M1-epacadostat were determined by adding
excess of each compound to each solvent. The homogeneous saturated solutions
were mixed at room temperature for 24 hours and centrifuged at 17,000 x g for 10
minutes to pellet insoluble drug. The amount of drug in the supernatants was
quantified by multiple reaction monitoring (MRM) using a Waters Acquity H-class
UPLC coupled to a Xevo TQS Micro (Waters, Milford, MA) system.
3.3.3. Folic Acid-P407 Conjugation
Toluene was added to P407 (12.6g, 1mmol), dehydrated by co-evaporation
then dissolved in 20 mL of anhydrous dichlroromethane

(DCM) and

dimethylaminopyridiine (DMAP 61 mg, 0.5 mmol) and triethylamine (TEA; 1.01g,
10 mmol). The reaction was cooled to 0°C, filtered, concentrated, and precipitated
in ether. The product was extracted with DCM/brine; the organic layer was dried
over anhydrous magnesium sulfide and then concentrated. The solvent was
precipitated in ether followed by separation via size exclusion chromatography
resulting in Tos-P407.
Tos-P407 (6.45g, 0.5 mmol) was dissolved in 20 mL dimethylformamide
(DMF) followed by the addition of sodium azide (0.33 g, 5 mmol) and stirred at
100°C overnight, filtered, and concentrated. The resulting product was dissolved
in DMSO and extracted with brine. The organic layer was removed by air drying
over anhydrous magnesium sulfide. The resulting product after purification was
azide-P407. Azide-P407 (3.84 mg; 0.3mmol) was added to triphenylphosphoine
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(0.8g; 3mmol) in THF. After 4 hours, 2 mL water was added to the reaction and
let stir overnight. The reaction was subsequently concentrated and precipitated in
ether, followed by purification via size exclusion chromatography.
Folic acid (FA; 0.5g) of was dissolved in 10 mL dimethylsulfoxide (DMSO)
plus 0.25 ml triethylamine. A 1:1 molar ratio of N-hydroxysuccinimide (NHS) (0.13
g) and N,N’dicyclohexylcarbodiimide (DCC; 0.23 g) was added. The mixture was
stirred overnight, then filtered. The filtrate was washed with ether and desiccated
overnight, forming a yellow powder.
Folate terminated P407 (FA-P407) was made from amine-P407 dissolved
in 20 mL DMSO. Folate-NHS (1.07 g, 2 mmol) was added into solution with the
amine-P407 and reacted overnight. The product was precipitated with ether and
purified by size-exclusion chromatography.

1H—NMR

confirmed addition of 1.9

folates to each polymer.
3.3.4. Epacadostat and M1-Epacadostat Formulation
3.3.4.1. High-pressure Homogenization
Using a top-down formulation approach, epacadostat and M1-epacadostat
were formulated with P407, P338, and P188. Drug to polymer ratio was 2:1 for
each surfactant used. Seventy-five mg of surfactant was initially dissolved in
water, then 150 mg of epacadostat was stirred with the solution for 1 day. The
suspension then underwent high pressure homogenization either until substantial
precipitation was observed (indicating insufficient interaction between drug and
polymer) or size as measured by DLS became stable. Formulations were
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homogenized at 10C. After homogenization, formulations were left sitting at
room temperature on the benchtop.
3.3.4.2. Poly (lactic co-glycolic acid) (PLGA) Formulation
PLGA (50 mg) (75:25, MW: 90,000-126,000, d,l-lactide-co-glycolide), was
added to 10 mg epacadostat (5:1) dissolved in 1 mL ethyl acetate as an oil
phase. Aqueous phase was prepared by dissolving DPSC (1,2-didodecanoyl-snglycero-3-phosphocholine) and (N-(Carbamoyl-methoxy peg-40)-1,2-distearoylcephalin sodium) mPEG2000DSPE (1:1 weight ratio) in chloroform. The
chloroform solution was dried under vacuum. 5mL water was added with probe
sonication for 30 second pulses for 5 minutes. The oil phase was added
dropwise under stirring to the aqueous phase, with the resulting mixture
sonicated 60 seconds followed by a 20 second break under ice bath, repeated
for several cycles. DCM was removed by air dying overnight. The resulting
encapsulation efficiency was 5%. The resulting formulation size was 202.5 nm,
with a 0.17 PDI and -47 mV zeta potential.
3.3.4.3. Micelle Formation
Micelles were formed by the solvent-evaporation method. Epacadostat
(12 mg) was added to 24 mg P407 and 200 µL ethyl acetate and desiccated
overnight. The resulting film was resuspended in 1 mL water.
3.3.4.4. Epacadostat-Captisol Complexation
One mL 20% Captisol in water (200mg/1mL) was added to 15 mg
epacadostat, vortexed 1-2 minutes, then sonicated 45 minutes.
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3.3.5. Isolation and Preparation of Monocyte-derived Macrophages (MDM),
Induction of IDO, and Cellular Uptake Studies
Human monocytes were obtained by leukapheresis from HIV-1 and
hepatitis B seronegative donors and purified by counter-current centrifugal
elutriation. Purified monocytes were cultured in DMEM supplemented with 10%
heat-inactivated pooled human serum, 1% glutamine, 50 μg/ mL gentamicin, 10
μg/ mL ciprofloxacin and 1000 U/ mL recombinant human macrophage colony
stimulating factor (MCSF) at a concentration of 500,000 cells/ mL at 37°C in a
humidified atmosphere with 5% CO2. Cells were plated at 2x106 cells per well in
12-well plates and cultured for 7 days [65]. To induce IDO, 100 ng/mL IFN-gamma
and 50 ng/mL LPS were given to the MDMs over 2 days (Figure 3.2) [153]. Cells
were treated with free drug or formulation after MDM differentiation, concurrent
with IDO induction. All formulations described were tested at 100 μM and 10 μM
over 48 hours. Drug levels were measured by UPLC-MS/MS.
3.3.6. Western Blot
Western blot assays were performed on MDM cell extracts using primary
antibodies against hu-IDO-1 (Ab-Cam), or beta-actin (Ab-Cam). Lysate protein
was loaded onto 1.5-mm-thick 4% to 15% gradient polyacrylamide precast gels
(Bio-Rad, Hercules, CA) and electrophoresed under denaturing nonreducing
conditions. Proteins from the gels were transblotted onto nitrocellulose
membranes (0.45mm pore size) at 60 volts for 1.5 hours at room temperature.
The membranes were blocked with 2.5 g BSA powdered milk in 50 mL TBST
(0.1%Tween 20 +tris-buffered saline (TBS)). Blots were incubated overnight at
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room temperature with primary antibody diluted 1:1000 in milk/bovine serum
albumin (BSA) solution. Blots were washed 3 times with TBST. One mL of
chemiluminescent dye was added, and the blots were exposed for 1-5 minutes.
3.3.7. Kynurenine and Tryptophan Quantitation
Kynurenine and tryptophan were extracted from cells and media. Upon
media collection, adherent cells were washed twice with PBS to remove excess
metabolite/drug. Cells were then gently lifted from the plate, counted in PBS, then
spun down at 5000 x g for 10 minutes. The PBS supernatant was removed, and
cells were stored in 100 μL 50% methanol until further analysis. Media was stored
at -80˚C until analysis. Media was warmed to room temperature and 100μL
removed for analysis after 3 minutes of vortexing and brief sonication. Metabolite
extraction was similar for media and cells: Ten μL internal standard (tryptophan
hydrochloride) was added along with 1 mL of ice-cold acetonitrile to samples, while
were vortexed for 3 minutes, followed by one minute of sonication. The samples
were centrifuged at 16000 x g for 10 minutes, and 1 mL of supernatant was
collected in a separate tube. After concentration via speed vacuum, samples were
reconstituted in 100uL 50% methanol/50% water with 0.1% formic acid.
For tissue and plasma samples: 100 μL plasma or 100 μL of a 5:1 water
diluted homogenate of tissue was collected and extracted via acetonitrile protein
precipitation, like cells and media.
Metabolites were quantified by multiple reaction monitoring (MRM) using
UPLC-MS/MS. Needle purge conditions were 40% methanol/40% butanol/20%
acetone/1% acetic acid. Needle wash conditions were 50% methanol/50%water.

52
Mobile phase A was 0.1% formic acid in water. Mobile phase B was 0.1% formic
acid in methanol. The column was a 30x4.6mm Phenomenex Luna PFP, initial
conditions were 0.5 mL/minute run isocratically for 5 minutes.

Tryptophan was

monitored at m/z 205.1-119.2, and kynurenine was monitored at m/z 209.1-146.2.
3.3.8. EC50 Measurements
MDM were cultured from human monocytes as described previously.
Concurrent with cytokine LPS and IFN-gamma stimulation cells were given varying
doses of drug (epacadostat and M1-epacadostat was dissolved in a solution of
20% cremophore/20% ethanol/60% PBS), with concentrations ranging from 1 nM
-10 μM. After 48 hours, media was collected and assayed for kynurenine. EC50
was deteremined as the half-maximal value of kynurenine in non-treated cells.
EC50 was calculated using 4-point logarithmic regression using GraphPad Prism
v7.
3.3.9. Pharmacokinetic (PK) Studies
Multiple PK studies were conducted in the characterization of parent
(epacadostat) compound vs prodrug (M1-epacadostat) nanoformulation. The pilot
study used Balb/cJ mice to evaluate epacadostat efficacy by injecting 5 mg/kg LPS
on day 0 (to theoretically induce IDO and stimulate kynurenine production) [154].
One day after LPS injection, mice were subcutaneously (SC) injected with
nanoformulation, parent compound, vehicle, or control. One day later mice were
sacrificed.
The following PK study was conducted to confirm IDO induction in mice and
measurable effect of parent compound on global kynurenine (with expected
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plasma reduction as seen by GSK). At time 0 mice were injected SC with either
50 mg/kg parent drug or nanosuspension. Blood was collected at 1,2,4 and 8
hours and mice were sacrificed at 8 hours.
In a subsequent study, route of injection was tested, comparing IM to SC,
and folate-targeted nanoformulation (FA-P407) was used (instead of M1epacadostat and P407). Four groups of mice (n=5) were given a single dose of
75 mg/kg epacadostat. The treatment groups were nanosuspension with folic acid,
free drug, nanosuspension with P407, and control. Blood was collected at 2, 4, 8,
and 24 hours. Tissues were collected at 4 and 24 hours. The follow up study once
again used mice on a folate-deficient diet (n=5 per group) to directly compare
nanoformulation to parent compound with different formulations and routes of
administration. This study tested 4 groups of mice (IM injected nanoformulation,
IM injected free drug solution, oral gavage free drug complexation, and oral gavage
spray dried dispersion) at 75 mg/kg parent compound or equivalents. Blood was
collected at time 2h,4h, and 8h with animal sacrifice at 24 hours.
A final study was carried out to test for extended formulation activity past 24
hours. Three groups of mice (n=5) were used to test the best performing
nanoformulation against the best performing free drug formulation from the
previous study (at 75 mg/kg or equivalents).

Plasma kynurenine, tryptophan,

prodrug, and drug were measured by blood draw on days 1, 3, 5 and 7. The
animals were sacrificed on day 7.
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3.3.10. Pharmacodynamic (PD) Studies
NOD/scid-IL-2Rγcnull (NSG) mice were reconstituted with human peripheral
blood lymphocytes (PBL). One week after reconstitution mice were bled and
monitored for reconstitution via flow cytometry. CD45+CD3+ gated CD4+ and
CD8+ populations were determined. Ten days later the mice were infected with
HIV-1ADA at a 50% tissue culture infected dose (TCID)50 of 104 by IP injection. Mice
received 4 daily doses of escalating nanosuspension drug treatments 3 days after
infection (150 mg/kg 2 consecutive days, 300 mg/kg the following 2 days). Two
days later, tissues were collected for immunohistochemistry (IHC), drug and
metabolite analysis, and viral load measurement.
3.3.11. Immunohistochemical Staining
For histological evaluation spleens, lymph nodes and lungs were removed
immediately after euthanasia and fixed with 4% paraformaldehyde overnight
followed by processing in the tissue processor Shandon Citadel 1000 (Thermo
Electron Corporation), according to the instrument instructions, and then
embedded in paraffin. Sections 5 micron thick were cut from the paraffin blocks,
mounted on glass slides and subjected to immunohistochemical staining with
mouse monoclonal antibodies for HLA-DR (clone CR3/43, 1:100) and HIV-1 p24
(clone Kal-1, 1:10) antibodies from Dako. The polymer-based HRP-a dna APconjugated anti-mouse and anti-rabbit Dako EnVision systems were used as
secondary detection reagents and developed with 3,3’-daminobenzidine (DAB).
All paraffin-embedded sections were counterstained with Mayer’s hematoxylin.
Images were obtained by an Optronics digital camera fixed to a Nikon Eclipse
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E800 (Nikon Instruments, Melville, NY) using MagnaFire 2.0 software. CD107a
(1:100 dilution (Dako) was also measured in tissue.
3.3.12. Viral Quantification
Real time PCR was performed with specific primers to detect viral RNA and
DNA in tissue samples. Bone marrow, spleen, lung, liver and gut were collected
at the time of euthanasia and stored at -80˚C until processing. RNA and DNA were
then isolated to perform viral quantification by real time PCR. Human CD45+ and
GAPDH primers were used for normalization.
3.4. Results
3.4.1. M1-Epacadostat Synthesis and Characterization
Using primarily one-step chemical substitution reactions, we added
hydrophobic moieties to the hydroxyl group. Creation of this ester bond is liable to
immediately cleave under physiological conditions due to hydrolysis or esterase
activity. To assess the ability of epacadostat prodrugs to be encapsulated in a
nanoformulation we tested them with PEG, P407, P366, and PLGA polymers.
Regioselectivity was confirmed via 1H-NMR coupled with ninhydrin and perioxide
staining. Prodrug stability was tested at 25°C and 37°C. Addition of a myristolic
acid epacadostat produced the most stable prodrug. The product was 12 times
less soluble in water than epacadostat.
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3.4.2. Folic Acid-P407 Conjugation
Folic acid was covalently attached to the amphiphilic block poloxamer 407
(FA-P407) was conjugated through DCC coupling [64]. The final product yielded
one folic acid molecule covalently linked to each end of P407.
3.4.3. M1-Epacadostat Nanoformulation and in vitro Characterization
The homogenized nanosuspension EC50 was the same as the free drug.
The epacadostat-P407 nanoformulation size was 167.8 with a pdi of 0.21 and
stable over a period of 2 months.

Parent drug levels in micelle and PLGA

formulations given to MDMs at 10 μM and 100μM were not significantly different
from parent compound in terms of uptake (~20 μg/million cells at 2 hours,
decreasing to undetectable levels after 48 hours). Though stable formulations,
these were abandoned due to low loading capacity. Kynurenine levels correlated
with drug levels, though parent drug and nanoformulation at 100 μM exhibited
similar inhibition (Figure 3.2 B) and uptake (not shown). Prodrug conversion to
parent compound ratio of the nanoformulation was consistently 50% over the 24
hours (data not shown). This indicated relatively quick conversation of the prodrug
to parent compound. Drug administration to macrophages was needed to induce
IDO as confirmed by western blot and may have slightly altered enzyme
expression (Figure 3.2 C).
3.4.4. PK Studies
The pilot mouse study produced superior IDO levels from nanoformulation
over parent compound in liver and kidney after 24 hours (3700 ng/g vs 1200 ng/g
in liver and 2000 ng/g vs 1200 ng/g in kidney). No differences in drug levels were
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seen in plasma. Additionally, no differences in plasma kynurenine were detectable
in any group, indicating the induction paradigm did not work systemically. Notably,
parent drug and nanosuspension produced lower levels of kynurenine locally
within spleen tissue (855 vs 672 ng/g, respectively). Measurement of kynurenine
in gut Peyer’s patches produced no noticeable differences. Notably in the follow
up 8-hour study, nanosuspension lowered kynurenine levels in plasma compared
to parent compound at 1 and 2 hours (5 ng/mL vs. 20 ng/mL at 1 hour, and 12
ng/mL vs. 23 ng/mL at 2 hours, respectively). Area under the curve (AUC) for
plasma was greater for the free drug over 8 hours, however substantial
unconverted prodrug (~15000 ng/mL) was observed in plasma at 2 hours and up
to 4 hours. Contrary to expectations, at 8 hours roughly 2 times more parent drug
was found in liver and brain of the parent drug treatment arm. The next study
extended treatment period to 24 hours and began testing different routes of
injection. IM injection produced slight but insignificant increases in plasma
kynurenine levels, but interestingly resulted in less basal kynurenine after 24
hours, indicating drug effect. A follow up 24 hours study with mice on folate
deficient diet [63, 75] produced positive results. Though plasma AUC was higher
for parent compound at this dose via IM injection, after 24 hours plasma levels
were significantly higher in nanosuspension compared to free drug (Figure 3.3A).
This corresponded with reduced kynurenine (a confirmed drug biomarker in cancer
treatment) favorable when compared to the free drug formulation (Figure 3.2.B).
Plasma tryptophan levels were unchanged (Figure 3.3.C). Tissue levels also
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indicated a depot formation in muscle of the nanoformulation and superior tissue
levels as compared to free drug (Figure 3.4. A, B, C).
The 7-day study produced similar results, with no effects seen after 1 day
of administration. Notably, plasma kynurenine was significantly lower for parent
and prodrug (58 and 62 ng/mL, respectively) at day 1.

This correlated with

detectable drug levels at day 1 (251 vs 160 ng/mL for nanosuspension and parent
drug, respectively). Drug was undetectable after day 1, and no differences were
observed in metabolite levels.
3.4.5. PD Studies
No differences were observed between viral DNA or RNA levels in control
HIV, versus nanoformulated treated HIV. No significant differences were observed
in CD45+CD3+CD4+ or CD45+CD3+CD8+ cells in plasma or in CD4/CD8 ratio
(Figure 3.6 A, B, C). No differences were observed in plasma viral load (Figure
3.6 D). No differences in tryptophan or metabolite levels were found in any tissues
except spleen (Figure 3.6 E, F). Plasma drug levels were low (100 ng/mL). In
addition to viral load, HIV infection was confirmed in these animals via p24 staining
and PCR (not shown), however IHC analysis did not indicate prevalence of CD8+
T cells or CD107a expressing cells (which would implicate CTL response) near
p24 infected cells in spleen, liver, gut, or lung.
3.5. Discussion
Of the epacadostat prodrugs constructed, only the benzyl and myristoyl
prodrug theoretical molecular weight was visible via mass spectrometry infusion.
However, the resulting 1H-NMR did not indicate addition of the benzyl group was
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complete at the expected shift near 6-7 ppm. Therefore, only the myristoyl prodrug
(M1-epacadostat) was advanced. Further pursuance of the benzyl compound
would likely require modification of the chemistry used, i.e. more base equivalents
(tBuMgCL) to the reaction to further its completion. If the resulting product was still
unable to be purified, crystallization methods could be pursued.
Our laboratory has synthesized several targeting moieties, including
mannose, folic acid, and hyaluronic acid. FA-P407 was used to initially screen
particle size, charge, and polydispersity of M1-epacadostat nanoformulated by
high-pressure homogenization.

The improvement in non-covalent bonding of

hydrophobic prodrugs translated to increased drug loading in prodrug
nanoformulation. EC50 studies were conducted similarly to those established in
literature [155].

Sources of variability in this experiment were IDO enzyme

expression and potential toxicity.
Though drug levels were improved in nanoformulation-dosed rodents,
macrophage drug sequestration may not correlate with drug tissue levels due to
local release of drug payload, especially given the minor differences seen in vitro.
To rule out the possibility of a different cell subset being the primary depot, future
works could measure drug content in different cell subsets (i.e. dendritic cells,
neutrophils) known to express IDO [142, 156].

Further, the phenotype of

macrophages may be related to IDO expression. Epacadostat is a competitive
antagonist and has been shown to not enzymatically degrade IDO. Therefore,
binding kinetics may be affected by IDO overexpression. Consistent enzymatic
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expression in cells should be further validated by western blot. Cell surface
markers (FACS) could be used to measure alterations in macrophage phenotype.
Though a biomarker in cancer, plasma kynurenine may not be a relevant
biomarker in mice for HIV. Tryptophan is controlled by TDO in the liver [157].
Therefore, its systemic and local levels may not be interpretable within the context
of IDO-1. Differences in T cell population may be unrelated to basal IDO activity
in normal mice. Feedback mechanisms inducing IDO activity and tryptophan
clearance that interfere with IDO activity measurements may not be present in the
hu-PBL disease model used. In that case, the best solution would be a new mouse
model.
Overall, despite a stable nanoformulation improving PK, translatable results
to PD were not seen. Not shown was CD8+ IHC data showing no difference in
CD3+CD8+ location with p24 in spleen, lymph, or lung tissues between control or
treated groups.

Further, granzyme B staining (a marker for CTL response)

indicated no differences between groups.
Taken together, it is possible the tightly controlled expression of IDO
combined with its involvement in chronic inflammation as well as adaptive
immunity may not be decipherable by an IDO inhibitor in the context of HIV.
However, future works could theoretically use in vitro modeling to examine a CTL
component. Dendritic cells (DC) could be cultured with autologous lymphocytes.
HIV antigen stimulation could then activate interferon pathways and induce IDO
and antigen presentation in DC. Optimized IDOi could then be added to the DC
culture. Antigen-primed IDOi treated CD8+ could be isolated and then transferred
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to a separate autologous cell culture with latently HIV infected (but reactivated)
CD4+ cells. CD8+ CTL viral killing abilities could then be evaluated through
surface expression of CD8+ CD107a, overall viral replication, and cell line survival.
Increased CD8+ CD107a expression, decreased viral replication, and decreased
cell line survival would indicate an improved CTL response.
Lastly, different mouse models, such as BLT mice, that more closely mimic
adaptive immune system components could be used for IDOi testing. Such testing
may require combinations of IDOi, ART, and ‘shock’ agents to see any effect.
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Scheme 3.1: Chemical scheme for M1-Epacadostat
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Figure 3.1: in vitro testing of epacadostat in MDM: (A) Setup for IDOi testing in MDM, (B) Inhibition of
IDO-1 by epacadostat and M1-epacadostat. (C) Western blot of IDO-1 expression normalized to betaactin
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Figure 3.2: Abbreviations: OG: oral gavage; SDD: spray-dried dispersion; nanosuspension: M1epacadostat FA-P407 nanoformulation. Pharmacokinetics of single administration of 75 m/kg (or
epacadostat equivalents) to Balb/C mice. (A) Plasma levels over 24 hours of the M1-epacadostat
nanosuspension (nanosuspension), epacadostat dissolved in captisol injected IM (free drug IM),
epacadostat in captisol formulated as a spray-dried dispersion (SDD), and epacadostat dissolved in
captisol given by oral gavage (Free Drug OG). (B) Plasma kynurenine levels over 24 hours (C)
Plasma tryptophan levels over 24 hours
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Figure 3.3: Pharmacokinetics of single intramuscular administration of 75 mg/kg (or epacadostat
equivalents) to Balb/C mice. Epacadostat levels in (A) Liver, (B) Spleen, and (C) Muscle. Note: Y axis
values are in ng/g.
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Figure 3.4.: Experimental setup for NOD/scid-IL-2Rγcnul mouse study. Two groups of mice (n=8) were
infected with HIV-1ADA. One group was treated with M1-Epacadostat, the other given no treatment.
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Figure 3.5: Results from PD study with nanoformulation in HIV-1 infected mice: (A) CD4+ human
T cells in plasma measured early (just before HIV-1 injection) and late (10 days after infection at
the last timepoint). (B) CD8+ human T cells in plasma. (C) CD4/CD8 ratio in pasma. (D) Plasma
viral load in M1-IDOi treated vs non-treated groups (E) Epacadostat levels in spleen (ng/g) and
plasma (ng/mL) at sacrifice timepoint (F) Tryptophan levels in spleen
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Chapter 4

Tenofovir Compounds
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4.1. Abstract
Using one and two-step chemical reactions, we added hydrophobic
moieties to TAF through alteration of the anime group.

Regioselectivity was

confirmed via 1H-NMR coupled with ninhydrin staining. Multiple compounds of a
prodrug library were formed through Schiff base or basic reactions using TEA
included hydrophobic moieties such as benzyl, heptyl, and myristoyl (fatty acid
chain). Co-crystallization of TAF prodrug with an FTC prodrug produced a
compound that exerted antiretroviral activities with a different metabolic route than
TAF. Two TFV ProTides were constructed, the first replacing the L-alanine on TAF
with an ester bonded docosanol L-phenylalanine. The second replaced the aryl
motif on TAF with an ester bonded docosanol. Nanoformulated prodrugs produced
superior cellular MDM uptake.
4.2. Introduction
Tenofovir (TFV) is an NRTI, a nucleotide analog of deoxyadenosine
monophosphate. Unlike typical NRTIs, it contains a stable phosphonic acid group
added to bypass a sluggish intracellular phosphorylation step. This linkage is
chemically and metabolically stable, as hydrolysis back to the nucleoside,
deamination, or glycosylation does not occur due to the acyclic nature of the
compound and a carbon bond between the sugar mimic and the adenine base
scaffold [158].

TFV cannot be orally administered, as at physiological pH a

dianion forms on two oxygens attached to the phosphorous, preventing effective
gut penetration. Though often linked to plasma concentration, true effectiveness
of TFV is reflected by intracellular TFV-diphosphate (TFV-DP) unbound to cell
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membranes or host proteins, and depends on a variety of factors such as
endogenous dATP, the cell type, the levels of cell activation, and expression of a
variety of cellular kinases [159, 160]. Recent strategies in NRTI development
focus on increasing the amount of ddNTP inside HIV-1 infected cells by attaching
lipid-modified phosphonate groups to the sugar portion of the NRTI, as evidenced
by success of tenofovir disoproxil fumarate (TDF). The ester-linked lipophilic
moieties added to the phosphorous are necessary to mask the charge brought by
addition of a physiologically charged phosphonate [161]. This confers additional
benefits of increased drug loading into cells through passive diffusion, and more
rapid conversion to active form, bypassing a “sluggish” cellular drug
phosphorylation linked with high substrate kinase specificity [162, 163]. The most
clinically successful NRTI prodrug strategy to date - as evidenced by tenofovir
alafenamide (TAF) - used an aryl motif and an amino acid ester to cover the
phosphonate group [164]. The concept of using an aryl group and an amino acid
group as side chains on the phosphonate is termed ProTide technology.
Properties commonly considered when choosing side chains on the phosphonate
in this technology are: lipophilicity, stability in plasma, ability to hydrolyze in cells,
and non-toxicity of byproducts. ProTide technology alone has seen 10 different
candidates in clinical trials for viral infections, and many more in development.
Numerous groups are producing ProTide libraries for treatment of viral infection
[165, 166]. To date NRTI prodrug candidates are optimized for oral dosage, and
therefore moderately to highly water soluble. A noticeable gap in literature exists
on alternative delivery methods of long acting ProTide compounds.
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4.3. Methods
4.3.1. M1-TFV Synthesis
Z-Phe-Odoc: Triethylamine (1.35 g, 1.86 mL, 13.36 mmol), imidazole (454
mg, 6.68 mmol) and HATU (3.81 g, 10.02 mmol) were added to a solution of ZPhe-OH (2 g, 6.68 mmol) and docosanol (2.4 g, 7.35 mmol) in a mixture of CHCl3
(25 mL) and DMF (25 mL) at 0ºC under an argon atmosphere. The mixture was
then heated at 45 °C for 48 h and concentrated. The crude product was diluted
with CH2Cl2 (100 mL), washed successively with 1 M HCl, and saturated NaHCO3
brine (80 mL each). The organic extract was dried over Na2SO4 concentrated. The
residue was purified by flash chromatography to give Z-Phe-Odoc (3.46 g, 85 %)
as a colorless solid.
H-Phe-ODoc: To a solution of Z-Phe-Odoc (3.46 g, 5.695 mmol) in a
mixture of anhydrous MeOH (20 mL) and CHCl3 (10 mL) was added Pd/C (1.4g,
40% wt). The reaction mixture was cooled to 0°C followed by drop wise addition of
triethylsilane (6.6 g, 9.1 mL, 59.95 mmol). The reaction mixture was then stirred
under an atmosphere of argon at room temperature for 16 h, filtered through Celite
TM ®

and then concentrated to give H-Phe-Odoc (quantitative yield), that was

precipitated from ether and used without further purification.
An excess of thionyl chloride (20mL) was reacted with TFV (6.3 mmol)
dissolved in chloroform (30mL) and triethylamine to give phosphonochloridated
TFV. The reaction was heated to 65°C and run for 2 days, yielding 4.5 grams of
crude product. Phenol (6.3 mmol) was dissolved in 10mL DMF, then Et3N was
added (6.3 mmol). The phenol solution was added to the phosphonochloridated
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TFV (6.3 mmol) from the previous step (pH =6) and stirred at 0°C overnight. The
product (TFV-phenol) was reacted with the H-phe-odoc linker (6.3 mmol). The
linker was dissolved in 10 mL chloroform and 10 mL DMF. ET 3N (3 equiv.) was
then added, followed by another 10 mL chloroform. Then TFV-phenol was added.
The reaction was run at 45°C overnight and purified via flash chromatography.
(Scheme 4.1).

The resulting product was formulated via high-pressure

homogenization using P407.
4.3.2. M2-TFV Synthesis
TAF (2.1 mmol) was dissolved in methanol and reduced by adding
palladium on carbon and triethylsilane. The resulting product was filtered, then
purified via flash chromatography. The purified product was reacted with HATU,
imidazole, 10 mL DMF, triethylamine (2.1 mmol), and docosanol (4.2 mmol) to give
a final product (Scheme 4.2). The resulting product was formulated via highpressure homogenization using P407.
4.3.3. TAF Prodrug Synthesis and Characterization
TAF (1.1 mmol) was added to 5 mL pyridine and dried down. Ten mL
additional pyridine was added, and the reaction cooled to 4°C. 150μL ET3N (2.2
mmol) was added, then 654 μL of phenyl nitro chloroformate (3.3 mmol). The
reaction was heated to 45°C and run overnight. The crude product was cooled on
ice followed by addition of 10 mL anhydrous DCM. To this mixture, 1.37 grams of
1-tetradecanol was added (5.5 mmol), then 640 mg DMAP (5 mmol) and 731 μL
ET3N (5 mmol). The reaction was run at 45°C under reflux overnight and purified
by flash chromatography (M1-TAF). M1-TAF was a yellowish gel.
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Additional TAF prodrugs were prepared using one step reactions. TAF (1.1
mmol.) was dissolved in pyridine, followed by addition hydrophobic moieties such
as benzyl chloride, decanoyl chloride, or heptyl chloride (2.2 mmol) and run
overnight. The resulting products were yellowish gels in low yield. To crystallize
M1-TAF, 1 mmol M1-TAF was dissolved in organic solvents and 3 mmol PFTC
prodrug (FTC with a 14-carbon chain linker attached, work currently submitted for
publication) was added. The resulting slurry was heated and then lyophilized,
producing a pink powder (M1TAF/F). The powder was nanoformulated via high
pressure homogenization.
4.3.4. TAF PLGA Development and Nanoformulation Characterization
A total of 80 mg poly (lactic-co-glycolic acid) (PLGA) (75:25, MW: 90,000126,000, d,l-lactide-co-glycolide), was added to 20 mg TAF (4:1) dissolved in 1mL
ethyl acetate as an oil phase. Aqueous phase was prepared by dissolving 1,2didodecanoyl-sn-glycero-3-phosphocholine (DPSC) and N-(Carbamoyl-methoxy
peg-40)-1,2-distearoyl-cephalin sodium (mPEG2000DSPE) in chloroform.

The

chloroform solution was dried under vacuum. Water (5 mL) was added and the
mixture probe sonicated. The oil phase was added dropwise to the aqueous
phase, with the resulting mixture sonicated 60 seconds followed by 20 second
break under ice bath, repeated for several cycles. DCM was removed by air dying
overnight. The next step was centrifugation for 5 minutes at 5000 x G, then 20
minutes at 14000 x G. The supernatant was aspirated, and pellet kept and
resuspended in 4mL phosphate buffered saline. The resulting size was 150 nm ±
4.87 with a zeta potential of -50mV ± 3.19.
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4.3.5. TAF-PLGA Characterization in vitro
MDMs were cultured as previously described. For uptake studies, cells
were treated with TAF, TAF co-crystal formulation or TFV-prodrug formulations.
At 1,3, and 8 hours cells were collected and assayed for drug content.
4.4. Results
The co-crystal of M1-TAF and PFTC (M1-TAF/F) maintained antiretroviral
activity for up to 15 days (not shown). This compound was not pursued due to the
PDI of the nanoformulation (>0.4), the difficulty in interpreting contributions of two
anti-HIV active compounds, the low innate EC50 of M1-TAF alone, and the difficulty
in reproducing M1-TAF synthesis. Other TAF prodrug synthesis attempts that
produced gel like substances were unsuccessful as their mass and structure could
not be resolved by infusion intro a mass spectrometer or 1H-NMR, respectively.
M1-TFV and M2-TFV were successfully synthesized and nanoformulated
with P407.

Notably, M1-TFV and M2-TFV prodrug nanoformulations both

promoted large amount of cellular uptake in MDM treated with 100 μM TFV
equivalents after 8 hours of administration (Figure 4.1). These levels were much
higher than TAF-PLGA levels at an identical dose. Preliminary long-term efficacy
indicated

antiretroviral

activity

was

present

from

the

TAF

co-crystal

nanoformulation.
4.5. Discussion
Production of a small hydrophobically altered TFV library produced 1
compound taken up robustly by MDM after 8 hours (~50 μg/mL). Short and longterm cytotoxicity studies should clarify if too much prodrug is getting inside cells.
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This can be determined by mitochondrial toxicity assays or observing cell
confluence (a decrease in confluence indicates cell death).

Further, prodrug

hydrolysis rates would be useful before moving into animals. EC50 studies when
combined with this data will determine if prodrug nanoformulations are enough to
advance to the next stage of treatment. Lastly, TFV-diphosphate levels will need
to be correlated to antiviral activity in multiple cell lines. M1-TFV holds the most
promise, likely due to similar metabolism to TAF as established in literature. The
aryl ring on the phosphonate place a crucial role after initial hydrolysis or
esterification of the amino acid chain, acting as a cyclic intermediate before being
cleaved away. Given the low amount of TFV-DP required for anti-HIV activity (1030 fmol [167]), and long intracellular half-life of TFV-DP, prodrug candidates
producing more active metabolite should be advanced.
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Scheme 4.1: L-phenylalanine-C22 linker synthesis
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Scheme 4.2: M1-TFV Synthesis
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Scheme 4.3: M2-TFV Synthesis
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Figure 4.1: Nanoformulation characterization in MDM: (left) MDM treated with 100μM of M1-TFV,
M2-TFV, or TAF-PLGA formulation for 24 hours. (right) Formulation characterization
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Chapter 5

Creation of a Phosphoramidate Pronucleotide
Nanoformulation of Lamivudine

(NM23TC)
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5.1. Abstract
A long acting (LA) hydrophobic and lipophilic lamivudine (3TC) was created
as a phosphoramidate pronucleotide (designated M23TC). M23TC improved
intracellular delivery of active triphosphate metabolites and enhanced antiretroviral
and pharmacokinetic (PK) profiles (as measured by prodrug levels in tissue and
plasma) over the native drug. A single treatment of human monocyte derived
macrophages (MDM) with nanoformulated M23TC (NM23TC) increased and
extended drug uptake, retention, intracellular 3TC triphosphates (3TC-TP) and
antiretroviral activities in MDM and or CD4+ T cells. PK assessment of NM23TC
administered to Sprague Dawley rats demonstrated sustained prodrug levels in
blood and tissues also for 30 days. The development of NM23TC remains a
substantive step forward in producing LA slow effective release ARVs for future
clinical translation.
5.2. Introduction
Antiretroviral therapy (ART) has revolutionized human immunodeficiency
virus type one (HIV-1) care and prevention by changing treatment outcomes from
certain death to viable active and high quality lives [1]. Despite such successes
notable needs remain. These include the stigma surrounding daily use
requirements, treatment fatigue and breaks in regimen adherence [168]. These, in
turn, speed viral drug resistance and longer-term adverse events. With these
needs in mind optimized HIV-1 treatment and prevention strategies were born and
long acting (LA) ARVs were created [53, 169]. Despite early efforts, the numbers
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of available LA drug formulations, the mandated frequency of injections and the
administered dosing volumes limit broad use [170]. Through innovative medicinal
and polymer chemistry our laboratories birthed the field of long acting slow
effective release ART (LASER LART) with definition as potent hydrophobic
lipophilic ARVs with stable longer-term physicochemical stability and ready scale
up [5, 6, 84].
As of today, two NRTIs that include tenofovir disoproxil fumarate,
lamuvidine (3TC) or emtricitabine (FTC), taken with the integrase inhibitor
dolutegravir are current “first line” combination ART [138, 171]. Whereas
administration is offered in a single pill the drug’s relatively short half-lives require
daily life-long administration. Due, in measure, to the stigma-associated with HIV
infection, oral drug lymphoid and brain drug tissue penetrance, inherent toxicities
and common malabsorption syndromes; opportunities for regimen improvement(s)
clearly abound [171] opening opportunities for LASER ART developments [6, 84,
100, 104]. Indeed, LASER ART is defined by the transformation of partially
hydrophobic antiretroviral drugs (ARVs) into water insoluble lipophilic prodrug
nanocrystals [5, 6, 102, 103]. These changes serve to improve ARV
pharmacokinetic and pharmacodynamic profiles [5, 6]. The translational potential
is based on the maintenance of an intact drug particle during broad temperature
and pH values [172]. Thus, advancing evidence demonstrates that LASER ART
could occupy a seat in next stage developments of LA ART injectables [84].
While allowing ease of scale up and long-term prodrug and particle stability
in first generation LASER ART these successes required further modifications if
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drug half-life extension could be converted from weeks to months. Moreover, slow
prodrug hydrolysis rates will be required along with ARV entry into “putative” viral
reservoirs [6]. To these ends based on what is now an extensive body of work
second generation LASER ART formulations have begun to be developed [5, 6,
101-103] In toto, its scientific foundation builds on the concept of transforming a
short acting ARVs into potent tissue targeted nanocrystals with expanded PK and
antiretroviral profiles. In the current report the ARV 3TC was transformed into a
sustained release and more potent medicine. Two component steps were
deployed. The first used chemical modification of 3TC’s primary hydroxyl or amine
groups to form a hydrophobic ester or carbamate prodrug derivative. The second
deployed ProTide technology based on successful prior works where “like”
conversions were made of sofosbuvir and tenofovir alafenamide [158, 173, 174].
However, the transformation is with a twist in that the current goal was to produce
a hydrophobic lipophilic prodrug. We posit that the creation of a 3TC nanocrystal
served to balance the drug particle’s physiochemical properties, potency and
membrane permeability [100, 175].
To complete these physiochemical modifications a structure-based
screening of a range of amino acid and phosphonate ester promoieties was
implemented. These culminated in the identification of a lipophilic sustained
release poloxamer coated and potent ARV nanosuspension as previously reported
for abacavir [101]. While the concept of ProTide technology is decades old [174,
176], its prior application focused singularly on affecting drug potency and safety
not in transforming them into LA formulations [177]. Indeed, current LA ARVs,

84
cabotegravir or rilpivirine, which have now advanced to phase III clinical trials [178,
179] are hydrophobic, facilitating their immediate use as injectables [180]. In
contrast, the ARVs used as ProTides possess high aqueous solubility [181, 182]
with poor conversion to LA nanosuspensions. Thus, transformation of 3TC into a
lipophilic ProTide nanocrystal is unique as it serves to facilitate prolonged
intracellular accumulation of 3TC triphosphate, improve its biodistribution together
with its potency. Our goal was to create a controlled and sustained intracellular
3TC delivery by closely maintaining its antiretroviral therapeutic levels.
5.3. Materials and Methods
5.3.1. Chemicals
3TC was purchased from Boc Sciences (Shirley, NY).

Phenyl

dichlorophosphate, L-alanine methyl ester hydrochloride salt, L-phenylalanine
methyl ester hydrochloride salt, N-(carbobenzyloxy)- L-phenylaline, docosanol,
dichloromethane (CH2Cl2), chloroform (CHCl3), N,Ndimethylformamide (DMF),
(CH3)2SO-d6, triethylamine (Et3N), diethyl ether, tetrahydrofuran (THF), tertButylmagnesium chloride solution ( tBuMgCl, 1.0M in THF), triethylsilane (Et3SiH),
Pluronic F127 (P407), 1-octanol, LC-MS grade water and methanol were
purchased

from

Sigma-Aldrich

(St.

Louis,

MO).

Distearoylphosphatidylethanolamine-methyl-polyethylene glycol conjugate-2000
(mPEG2000-DSPE) was purchased from Corden Pharma (Cambridge, MA). 1[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]

pyridinium

3-oxid

hexafluorophosphate (HATU) was obtained from Chem Impex Intl Inc. (Wood
Dale, Illinois). Palladium, 10% on activated carbon, was purchased from STREM
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Inc. (Newburyport, MA). All the chemical reactions were performed under a dry
argon atmosphere. Flash chromatography was performed using 32-63 μm flash
silica gels from SiliCycle Inc. (Quebec, Canada). Reactions were monitored by
thin-layered chromatography on precoated silica plates (250 μm, F-254 from
SiliCycle Inc.). The compounds were visualized by UV fluorescence.

Heat-

inactivated pooled human serum was purchased from Innovative Biologics
(Herndon, VA). CEM-SS cells were obtainedlin from the National Institute of
Health.
5.3.2. Linker Synthesis
H-Phe-ODoc was conjugated as previously described ([61], Chapter 4)
dicholorophosphate conjugation: The amino acid ester (1 mol equiv.) and phenyl
dichlorophosphate (1 mol equiv.) were suspended in anhydrous CH2Cl2 (15 mL)
and cooled to -78°C in a dry ice/ acetone bath. To this mixture, a pre-cooled (78°C) solution of anhydrous trimethylamine (2 mol equiv.) in CH2Cl2 was added
drop-wise, and the resultant solution was stirred and gradually warmed to room
temperature over 32 h under an inert argon atmosphere. The reaction mixture was
concentrated on a rotary evaporator to yield a white solid that was suspended
into diethyl ether and filtered. The filtrate was concentrated to give aryl aminoacyl
phosphochloridates that were used in the next coupling step without further
purification.
5.3.3. M23TC Synthesis
3TC (1.0g, 4.36 mmol, 1 equivalents) was dried azeotropically from
anhydrous pyridine (10 mL), resuspended in anhydrous THF (30 mL), cooled to -
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78°C, followed by addition of tBuMgCl (5.23 mmol, 1.2 equivalents) and allowed to
stir for 15 minutes under an argon atmosphere. A solution of aryl phenylalanyl
docosyl ester phosphorochloridate (2.48g, mmol, 1 equivalent) dissolved in THF
(20 mL) followed by dropwise addition to the 3TC anion at -78°C. The reaction
mixture was gradually warmed to room temperature and stirred for 48h after which
M23TC was isolated by flush chromatography purification and lyophilized to form
a colorless powder (67% yield).

1H-NMR, 13C-NMR

and

31P-NMR

spectra were

recorded on a Varian Unity/Inova-500 NB (500 MHz; Varian Medical Systems Inc.,
Palo Alto, CA, USA.

FTIR was performed using a Spectrum Two FT-IR

spectrometer (PerkinElmer,Waltham, MA, USA).

Molecular weight was

determined by compound infusion on a Waters TQD triple quadrupole mass
spectrometer (Waters, Milford, MA).
5.3.4. Prodrug Characterization
5.3.4.1. Plasma Stability
To evaluate prodrug stability, 100 µL plasma from different species (rat,
human, mouse, and rabbit) was incubated with 1 µM of M23TC in non-saturating
conditions. Triplicate samples for each species and timepoint were kept in amber
glass vials on a shaker at 37°C with slow shaking. At 0 minutes, 2 hours, 6 hours,
and 24 hours after incubation, 900 µL of methanol was added to each vial, vortexed
3 minutes, then stored at -78°C until analysis. To account for non-specific binding
two negative controls were used at time 0. First, 100 µL ice cold plasma was
added to 900µL MeOH followed by prodrug addition. Second, at time-0 100%
HPLC-grade methanol was immediately added to the prodrug plasma mixture.
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Upon collection, samples were vortexed for 3 minutes, centrifuged at 16,000 g for
10 minutes, and transferred into new tubes for evaporation. Samples were then
reconstituted in 80% methanol (100 µL), centrifuged at 16000 g for 10 minutes and
then quantitated by UPLC-MS/MS.
5.3.4.2. Solubility of M23TC in Water and Octanol
Solubilities of 3TC and M23TC were determined by adding excess of each
compound to water or 1-octanol. The homogeneous saturated solutions were
mixed at room temperature for 24 hours and centrifuged at 17,000 x g for 10
minutes to pellet insoluble drug. The amount of drug in the supernatants was
quantified by UPLC-MS/MS. Chromatographic separation was performed with an
ACQUITY UPLC using CSH analytical column (2.1×100 mm, 1.7µm; Waters)
equipped with a guard column (Waters, Milford, MA). The following transitions
were monitored for M23TC: m/z 841.60→111.99 and m/z 841.60→211.98. LC
conditions were isocratic and run at a flow rate of 0.35 mL/min for 7 minutes.
Mobile phase A was 10mM ammonium bicarbonate pH 7.2, while mobile phase B
was 100% methanol. Conditions were 98%B, 2% A. The internal standard (IS)
used was a darunavir prodrug with stearyl attached (MW 630). The IS transition
was monitored from m/z 631.2-234.5.
5.3.4.3. Half-maximal Effective Concentration (EC50) in Monocyte-derivedMacropahges (MDM)
Human monocytes were isolated as previously described [67].

Briefly,

human monocytes were isolated by leukapheresis from HIV-1 and -2 and hepatitis
B seronegative donors, then purified by countercurrent centrifugation. Monocytes
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were cultured in macrophage colony-stimulating factor media (MCSF) with 50
μg/mL gentamicin and 10 μg/mL ciprofloxacin in DMEM for 7-8 days, to produce
MDM. MDMs were plated in a round bottom 96 well plate (80,000 cells/well) were
exposed to NM23TC or 3TC treated media in concentrations ranging from 0.01nM10 μM in tenfold dilution increments for 60 min and replaced with non-drug HIV1ADA media at an MOI of 0.1 for 4 hours. After 4 hours, infection media was
removed, and the cells were incubated an additional 10 days in the presence of
the same concentration of drug prior to infection. Half media changes were done
every other day. After 10 days of infection, culture media was collected to measure
HIV-1 reverse transcriptase activity as previously described [34].
5.3.4.4. EC50 in CEM-CD4+ Cells
CEM-CD4+ cells were cultured in suspension in 96 well plates, centrifuged
at 650 x g and re-dispersed in 100 μL drug-containing media. After 60 minutes,
cells were challenged with HIV-1NL4-3-eGFP (MOI 0.01) by spin-inoculation followed
by 16 hours of incubation in drug-containing media. The following day, cells were
washed 2 times with PBS to remove virus and drug-containing media was
replaced. Every 2 days, cells were centrifuged at 650 x g and exchanged with
fresh drug-containing media.

Ten days post HIV-challenge, supernatant was

collected for RT activity. Reverse transcriptase activity was measured in culture
media. The EC50 was calculated using sigmoidal 4-point logarithmic regression
from RT activity using GraphPad Prism v7.
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5.3.4.5. MTT Viability Assay in MDM
Human monocytes were isolated as previously described [183]. Monocytes
were cultured 7-10 days in 48 well plates (200,000 cells/well) with DMEM
supplemented with 10% heat-inactivated pooled human serum, 1% glutamine,
10 µg/mL ciprofloxacin, and 50 µg/mL gentamicin in a 37°C 5% CO2 incubator. A
stock solution of each drug in DMSO was serially diluted in DMEM to produce
concentrations ranging from 1-200 μM. Cells were treated for 24 hours, washed
and

incubated

with

200

μL/well

3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide) MTT solution (5 mg/mL) for 45 minutes. Upon MTT
solution removal, 200 μL/well of DMSO was added and absorbance measured at
490 nm on a SpectraMax M3 plate reader with SoftMax Pro 6.2 software. Samples
were normalized to % of non-treated controls.
5.3.4.6. Live-Dead assay in CEM CD4+ T Cell line
CEM CD4+ cells were added to a U-bottom 96 well plate at 100,000 cells
per well in RPMI media with 10% fetal bovine serum, 1% penicillin, and 1%
streptomycin and treated with 3TC or M23TC as described for MDM. After 24
hours, cells were centrifuged at 650 x g, dispersed in PBS, centrifuged again at
650 x g, and resuspended in PBS. Excitation dye (0.1 μL/million cells); Molecular
Probes, Live/Dead Fixable Dead Cell Stain Kits) was added to each well. Cells
were excited at 488 nm and monitored at 530 nm excitation; % dead cells were
determined by flow cytometry. Live cells were determined as 100%-%dead cells.
Identical MTT measurements as done in MDM were used as confirmation.

90
5.3.5. M23TC Nanoformulation
Poloxamer 407 (P407) was premixed with M23TC in PBS for at least 1 day
(2:1 drug:polymer).

It was prepared using direct synthesis by high-pressure

homogenization (Avestin EmulsiFlex-C3; Avestin Inc, Ottawa, ON, Canada). The
solution underwent high-pressure homogenization at 4C, 12,000 psi until the
desired particle size was achieved. Particle size, PDI, and zeta potential were
determined by dynamic light scattering (DLS) using a Malvern Nano-ZS
(Worcestershire, UK). Nanoparticle morphology was analyzed by transmission
electron microscopy (TEM).
5.3.6. Cell Uptake in MDM
MDM were cultured in 12 well plates and were treated with media containing
100 μM of NM23TC or 3TC and treated similarly to earlier works [5, 6]. At 2, 4 and
8 hours post treatment, media was removed, adherent MDM washed twice with
PBS and scraped into 1mL PBS. Cells were counted using an Invitrogen Countess
Automated Cell Counter (Carlsbad, CA), pelleted by centrifugation at 16000 x g.
The cell pellet was reconstituted and sonicated in 200 µl methanol followed by
centrifugation at 20,000 x g for 20 min. The supernatant was analyzed for drug
content using LC/MS-MS.
5.3.7. Nanoparticle Morphology
The morphology of drug loaded NPs was determined by scanning electron
microscopy (SEM) on a Hitachi S4700 field-emission scanning electron
microscope (Hitachi High Technologies America Inc, Schaumburg, IL, USA).
Particle surface morphology was characterized by transmission electron
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microscopy (TEM) using a Hitachi H7500 Transmission Electron Microscope
(Hitachi High Technologies America Inc, Schaumburg, IL, USA).

For TEM

analysis, the NP suspensions were diluted in Milli-Q water and placed onto a
copper grid and air-dried at room temperature. For contrast enhancement, one
drop of a 2% aqueous solution of sodium phosphotungstate was used as a
negative stain.

The images were recorded under bright-field conditions with

exposure times of 2 sec and an accelerating voltage of 200 kV.
5.3.8. Drug Loading and Encapsulation Efficiency (EE)
The amount of drug encapsulated in the polymeric matrix was determined
by high performance liquid chromatography (Waters Breeze HPLC system, Waters
Inc., Milford, MA, USA) with UV/Vis detection (267 nm). Freeze-dried NPs (1 mg)
were sonicated in 50 μl THF, diluted with 1 ml methanol, vortexed for 10 s, then
centrifuged at 10,000 ×g for 20 min. The supernatant was further diluted in mobile
phase (100% MeOH, later followed by a 0.2 mm (polyvinylidene fluoride) PVDF
syringe filter). The sample components were separated on an Atlantis reversed
phase C8 column ((3.1 μm, 100 × 4.6 mm), Waters, Boston, MA) using a flow rate
of 0.5 ml/min. Percentage drug loading was calculated as the weight percentage
of M23TC encapsulated in a given mass of lyophilized NPs.

The EE was

calculated as (actual amount of drug encased in NPs) / (initial amount of drug used
in NPs preparation) × 100%.
5.3.9. Cell Uptake in CEM CD4+ T Cells
CEM-SS cells suspended in RPMI media were then seeded at 1 million
cells/well and incubated at 37°C for 30-45 minutes. Cells were centrifuged at 650
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x g for 5 minutes, the supernatant was discarded and replaced with 100µM of
NM23TC or 3TC treatment media. At 4 and 8 hours post treatment media was
removed. Cells were washed, collected, counted, and pelleted as described for
MDM. Drug levels were measured using UPLC-MS/MS as described above.
5.3.10. Cell Retention in MDM
For drug retention measures, the cells were incubated with 100µM of drug
for 8 h. Drug containing media was removed and cells washed twice with PBS and
replaced in media without drug, followed by half media changes every other day
until collection. At days 1-30, cells were washed with PBS to remove extracellular
drug, followed by intracellular drug quantitation. Drug levels were normalized to
the number of live cells.
5.3.11. 3TC-Triphosphate (3TC-TP) Measurement in Macrophages and CD4+
T Cells
Intracellular 3TC-TP was extracted from cells and levels quantified as
follows. MDM were treated with 100 μM NM23TC. At 4, 8, 12, 24 and 48 hours
after treatment, MDM were washed with PBS to remove excess free drug. The
cells were then collected in 70% methanol. 3TC-TP from MDM was extracted as
follows. Sep-Pak QMA cartridges (360 mg, 37-55 μm; Waters, Milford, MA) were
used to separate 3TC-TP from their mono- and di-phosphate counterparts. The
QMA cartridges were conditioned with 10 ml of 500 mM KCl, followed by 10 ml of
5mM KCl. Sample (200 μL) was loaded onto the cartridges and washed with 14
ml of 75 mM KCl.

The triphosphate fraction was eluted with 3 ml of 500 mM KCl.

The pH of the TP fraction was lowered to 4.25 by adding 15 μl ammonium acetate
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buffer (pH 4, 10 mM) per ml eluate, and dephosphorylated by adding one unit of
type XA sweet potato acid phosphatase (Sigma-Aldrich) per ml eluate (about 3.4
μL per sample) and incubating at 37 °C for 45 min. Ten μL of 15N213C-3TC and d4ABC internal standard was then added. Samples were then loaded onto Waters
OASIS HLB cartridges (60 mg, 30 μm; Waters, Milford, MA) pre-conditioned with
3 ml 100% methanol and 3 ml MS-grade water and washed with 3.5 ml MS-grade
water to remove salts. The converted 3TC was then eluted with 1.5 ml of 100%
methanol and evaporated under vacuum. Once dry, the residue was reconstituted
with 100 μl of 25% methanol and stored at -80°C until UPLC–MS/MS analyses.
Chromatographic separation was performed with an Waters ACQUITY UPLC
using CSH analytical column (2.1×100 mm, 1.7μm; Waters, Milford, MA) equipped
with a VanGuard C18 (Waters) guard column. Mobile phase A was ammonium
bicarbonate buffer (pH 7, 7.5 mM) and mobile phase B was 100% methanol. The
flow rate was 0.25 ml/min. The initial mobile phase composition was 12% B for the
first 2.5 minutes, gradually increased to 30% B over 4 minutes, gradually increased
again to 95% B over 3.5 minutes, and then held constant for 1 minute. Mobile
phase B was then reset to 12% over 0.25 minutes and the column was equilibrated
for 2.75 minutes before the next injection. The total run time was 13 minutes [184].
5.3.12. Measures of Antiretroviral Activity
To assess long-term antiretroviral efficacy, MDM were treated with 100 μM
NM23TC or 3TC as described above for 8 hours. After treatment, cells were
washed with PBS and cultured with fresh media without drug, followed by halfmedia exchanges every other day. At days 1, 5, 10, 15, 20, or 30 after treatment,
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cells were challenged with HIV-1ADA at a multiplicity of infection (MOI) of 0.1 for 16
hours. HIV-1ADA media was then replaced with fresh media. Ten days after viral
challenge culture media was analyzed for reverse transcriptase activity, while
adherent MDM was fixed with 4% PFA and HIV-1 p24 protein expression assessed
by immunocytochemistry [66, 67, 114].
5.3.13. Toxicology, Pharmacokinetics (PK) and Drug Biodistribution (BD)
For pharmacological studies, Sprague Dawley rats (Jackson Labs, Bar
Harbor, ME, USA) were administered a single 75 mg/kg 3TC-equivalent dose of
3TC or NM23TC intramuscularly (IM) into the caudal thigh muscle to determine PK
over 4 weeks. Whole blood and tissue samples were analyzed by LC-MS/MS to
determine parent and prodrug levels. 3TC-TP levels were measured in lymph
nodes and spleen at day 28. Short-term toxicity assessment was also conducted
in Sprague Dawley rats with bleed timepoints at 1,3, 7 and 14 days at a 45 mg/kg
dose of NM23TC (3TC equivalents) or control (PBS). Tissue was collected at 14
days. Serum chemistry and white blood cell counts were measured. White blood
cells were quantitated using a VetScan HM5 (Abaxis Veterinary Diagnostics, Union
City, CA, USA) and serum chemistry analysis was done using a VetScan VS-2
instrument (Abaxis Vetinary Diagnostics, Union City, CA, USA).
5.4. Results
5.4.1. M23TC Synthesis and Characterization
A 3TC ProTide was synthesized by coupling an aryl phenylalanyl docosyl
ester phosphorochloridate with drug in the presence of tBuMgCl [185] and THF to
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form M23TC. The chemical yield of 65% after purification was observed (Figure.
1A, B). The chemical structure was characterized by 1H-NMR (M23TC), (500 MHz,
(CD3)2S=O): 7.88 (d, J = 7.3 Hz 1H), 7.60 (app. d, J = 7.6 Hz 1H), 7.10-7.35 (m,
8 H), 7.03 (app. d, J = 7.9 Hz 2H), 6.15-6.29 (m, 1H), 5.65-5.75 (m, 1H), 5.19-5.29
(m, 1H), 3.92 (br, 5H), 3.35-3.48 (m, 4H), 2.90-3.02 (m, 1H), 2.75-2.85 (m, 1H),
1.42 (br, 2H), 1.14-1.33 (m, 38H), 0.85 (br, 3H), 13C-NMR (125 MHz, (CD3)2S=O):
δ 172.4, 165.6, 154.6, 150.6, 140.5, 137.0, 129.5, 129.3, 128.2, 126.6, 124.5,
119.9, 94.4, 86.9, 81.4, 69.8, 66.7, 64.5, 56.2, 35.5, 31.4, 29.1, 28.7, 27.9, 25.3,
22.1, 13.9), and

31P-NMR

(31P NMR (202 MHz, (CD3)2S=O); 3.56, 3.35). The

broad singlet at 0.85 ppm and multiplets at 1.14-1.33 ppm correspond to the
terminal methyl and methylene protons of the docosyl ester. Chemical shifts at
7.10-7.35 ppm represented the aryl and phenylalanine masking promoieties
(Figure 6A). Analyses of

13C-NMR

(Figure 6B) and

31P-NMR

(Figure 6c) spectra

further confirmed successful synthesis of M23TC. Doubling of peaks in the carbon,
proton and phosphorous spectra demonstrate formation of two isomers at the
phosphorous atom. Further chemical characterization of M23TC by FTIR showed
absorption bands at 2845 cm-1 and 2852 cm1 corresponding to asymmetric and
symmetric C-H stretches from the long chain fatty alcohol (Figure 1C, D). Infusion
into a Waters Xevo TQ-S micro triple quadrupole tandem mass spectrometer
confirmed a molecular mass ion of 841.54, which corresponds to M23TC with one
phosphochloridate modification (Figure 7D).
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5.4.2. Physicochemical Characteristics of M23TC
M23TC showed > 1000-fold reduced aqueous solubility compared to native
3TC. This result confirmed the expected hydrophobicity produced from the lipid
conjugate. The solubility of M23TC in 1-octanol was 130 mg/mL, confirming a
substantial increase in prodrug lipophilicity (Figure 1E). Based on water solubility
calculations, we determined the stability of M23TC in PBS and plasma of multiple
mammalian species. M23TC was stable in PBS, while plasma incubation resulted
in prodrug degradation of < 30% over 24 h (Figure 1F). To further evaluate
potential biological changes of the modified 3TC we measured mitochondrial
function by MTT and cell viability by a live/dead assay. No adverse effects on
mitochondrial function or cell viability were observed with 200 µM and 50 μM in
MDM (Figure 2A) or CEM CD4+ T cells, respectively (Figure 2B). Reflective of
M23TC’s

lipophilicity,

efficacy

studies

were

performed

using

prodrug

nanosuspensions (NM23TC) to overcome poor aqueous solubility. The EC50 of
NM23TC was improved compared to 3TC (6.2 nM and 19.4 nM, respectively;
P=.6121) in MDM (Figure 2C). EC50 testing of NM23TC in CEM CD4+ cells
showed a modest decreased potency compared to native 3TC (79.7nM and 35.4
nM, Figure 2D). TEM images showed intracellular presence of nanoformulation
after short-term treatment (Figure 2 E, F, G, H).
5.4.3. Characterization of NM23TC
We generated P407 M23TC nanoformulations (NM23TC) by high-pressure
homogenization suspended in PBS. Drug encapsulation efficiency of the
synthesized NM23TC nanocrystals was 72%. The size, polydispersity index (PDI),
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and zeta potential of NM23TC nanocrystals were 189.5 ± 6.1 nm, 0.26 ± 0.01, and
-21 ± 0.2 mV, respectively, and remained stable at 25°C for at least 30 days (Figure
3A). We next evaluated NM23TC nanoparticle morphologies by TEM (Figure 3B).
NM23TC exhibited uniform spherical particle shape with diameters in the
nanometer range. Particle stability, uniformity, zeta potential, and EC 50
measurements supported the formulation integrity.
5.4.4. Nanoparticle-cell Interactions
To characterize HIV-particle interactions we evaluated cellular uptake and
conversion of M23TC to 3TC-TP in MDM and CEM CD4+ T cells. These were
determined following a single exposure to equivalent concentrations for all
compounds and formulations. NM23TC was readily taken up by MDM with an
intracellular drug concentration increasing to 48 µg/106 MDM at 24 hours (Figure.
3C), more than 50 times higher than what was seen for the native drug (< 0.5
µg/106 cells over 24 hours). NM23TC conversion to active metabolites was also
improved reaching maximum 3TC-TP levels at 8 hours (16,798 fmol/106 cells) and
once again significantly greater than 3TC alone (4,747 fmol/10 6 cells) (Figure 3D).
Uptake studies in CEM CD4+ T cells showed rapid prodrug uptake (18.3 μg/mL)
and conversion of prodrug to 3TC-TP (4067 fmoles/million cells) after 8 hours
(Figure 3E, F). 3TC-TP in a CEM CD4+ T cells was accelerated in time. Taken
together, these findings demonstrate substantial conversion to 3TC-TP in both
HIV-1 target cells (MDM and CD4+ T cells).
Prior data from our laboratories demonstrate long-term storage capacities
for nanoformulation in MDM [81, 82]. Thus, NM23TC was next evaluated in MDM
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for drug retention.

In drug particle retention studies, NM23TC facilitated the

presence of 3TC in cells for up to 30 days (14 µg/106 cells) while native 3TC
treatments showed no presence within hours (Figure 4A). Intracellular active drug
metabolites showed that 3TC-TP was retained by MDM at levels of 3,088 fmol/106
cells at day 1 and fell below the limit of quantitation by day 10 following native 3TC
treatments.

However,

NM23TC

exhibited

sustained

active

metabolite

concentrations of 9,874 and 839 fmol/106 cells at days 1 and 30, respectively
(Figure 4B). Prodrug levels in MDM were readily detected. Media collected from
retention studies showed that M23TC was released from MDMs in high
concentrations.

Substantial release of prodrug was detected at 1 day (1685

µg/mL) and followed by sustained long-term amounts of prodrug (229.6 ng/mL) up
to day 30 (Figure 4C).
5.4.5. Antiretroviral Activities
To assess whether enhanced intracellular 3TC-TP levels from NM23TC
would translate into improved antiretroviral activities, MDM were treated with
NM23TC or 3TC for 8 hours at 100µM, followed by drug washout and HIV-1ADA
challenge at five-day intervals for up to 30 days. In cells treated with NM23TC no
HIV-1p24 staining or RT activity was seen through 30 days (Figure 4 D, E). In
contrast, viral breakthrough was observed within one day of treatment with native
3TC. Cross validation by HIV-1p24 antigen staining paralleled RT results,
demonstrating substantial inhibition for up to 30 days after a single exposure to
NM23TC in MDM. Decreased concentrations of NM23TC resulted in coordinate
increased RT activity (Figure 4F). These findings demonstrate that NM23TC
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improves intracellular delivery of 3TC-TP with enhanced drug potency and
sustained antiretroviral efficacy.
5.4.6. Toxicology, PK and BD
Although NM23TC formulation was manufactured using FDA-approved
excipients and clinically relevant prodrug lipid linkages we evaluated formulation
toxicity over 2 weeks in rats, collecting blood and measuring serum chemistry.
Comparisons were made between 45 mg/kg IM single-injected NM23TC and
control untreated animals. There were no differences in serum chemistry values
between NM23TC and untreated animals. No adverse events regarding weight,
movement or animal behavior were observed in prodrug formulation-treated
animals (Figure 7 A, B). For PK and BD studies, male Sprague Dawley rats were
administered 45 mg/kg 3TC equivalents of NM23TC (n=3) or 3TC via
intramuscular injection to assess drug PK and BD parameters.

Single

administration of NM23TC provided sustained and high prodrug concentrations in
blood at one month (Fig. 5A; study timeline Figure 7C). At days 1 and 28, prodrug
concentrations in blood were 711 and 103 ng/mL, respectively. In contrast, 3TC
displayed higher native drug concentrations in blood at day 1 and fell below the
limit of quantitation by day 7 (data not shown). PBMC 3TC-TP levels for NM23TC
were detectable but low for the duration of the study (<50 fmoles/million cells)
Notably, spleen (2,787 ng/g), liver (495 ng/g) and lymph nodes (4,471 ng/g)
exhibited high M23TC concentrations at day 28 (Figure 5B, -C and -D) with
detectable levels of 3TC-TP in spleen (74.4 fmoles 3TC-TP/million cells) and
lymph nodes (21.7 fmoles 3TC-TP/million cells) at day 28 (Figure 5 C and D). As
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expected, native drug treatment displayed low drug levels (at or below the limits of
detection) in plasma and tissues after one day (data not shown). The high M23TC
levels in tissues compared to drug concentrations in plasma or blood suggest that
tissues, especially spleen and lymph nodes, could serve as drug depots for
sustained release of M23TC. Substantial improvements in potency and longer
duration of intracellular action of NM23TC could potentially enable reduced dosage
and infrequent drug administration.
5.5. Discussion
A first generation modification of a 3TC prodrug produced modest
improvements in the drug’s half-life [100, 175] with limited modifications in
intracellular drug levels [184]. Thus, we pursued the design and development of a
second generation LA 3TC ProTide (M23TC) nanoformulation (NM23TC). The
data showed improved drug potency, lipophilicity, stability and antiretroviral activity
facilitating its intracellular and tissue drug delivery profile. The M23TC design
included the addition of a phenylalanine based on its inherent hydrophobicity.
ProTide additions enhanced 3TC’s potency with combinations of aryl and either L–
alanine or L-phenylalanine methyl esters used as phosphate masking promoieties
[177, 185]. The rationale for use of a docosyl ester for the prodrug synthesis was
based on docosanol having inherent antiviral activity, including synergistic effects
on activities of nucleoside analogs [186, 187]. Extensive prior good laboratory
practice genotoxicity studies performed in rats, rabbits and dogs demonstrated no
mutagenic or genotoxic effects after docosanol exposure, supporting the proposed
safety of our lipid-modified 3TC ProTide, [188, 189]. In parallel studies, docosanol
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exhibited no untoward effects on reproduction behavior in rats and rabbits [188,
189]. Improvement of 3TC hydrophobicity and lipophilicity, nonetheless, enhanced
the stabilization and conversion of the prodrug into LA ART nanosuspensions also
extending the apparent drug half-life.
The development of LA ARV nanomedicines presents attractive alternatives
for the prevention and treatment of HIV-1 and for co-morbid infections [32-34]. The
potential of LASER ART to improve drug BD and extend ARV half-life are now
proven [5, 6, 63, 75]. Indeed, notable advances are highlighted by success of CAB
and RPV LA. These were shown to elicit comparable antiretroviral activities to daily
oral three-drug regimens during maintenance therapy [53]. However, limitations
abound that include rapid ARV metabolism and inherent physicochemical
limitations. To overcome such concerns, we generated lipophilic LASER ART
nanocrystals to affect drug potency and ensure rapid transport across
physiological barriers [5, 6, 100, 103, 104]. The creation of such formulations
served to maximize drug loading with optimization of excipient usage while
maintaining scalability and storage for potential broad use [172].
We reasoned that drug modifications would be required if a “true” LA
formulation was to be obtained for a spectrum of ARVs. Therefore, our laboratory
and others explored modification of the primary hydroxyl or amine groups in 3TC
to form hydrophobic ester or carbamate prodrug derivatives in attempts to balance
the drug’s physiochemical properties and potency. These served to facilitate
membrane permeability [100, 175]. However, such strategies only provided limited
intracellular drug levels [184]. Notably, prior attempts to use ProTide technology
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that has proven effective in the discovery of sofosbuvir and tenofovir alafenamide
failed to provide enhancement in drug potency when applied to 3TC [190-192].
Thus, we developed alternative strategies that could potentially overcome
formulation challenges for short acting ARVs through structure-based screening of
a range of amino acid and phosphonate ester promoieties that culminated
in identification of a lipophilic sustained release formulation. Here poloxamer
coated abacavir (ABC) ProTide nanosuspension (NM3ABC) was made with
improved antiretroviral activities [101]. It is worth noting that while the concept of
ProTide technology was established a few decades ago [174, 176], its application
to NRTIs had focused on improvement of drug potency and safety profile and
that none have appeared as part of long-acting formulations. Also, unlike long
acting formulations of CAB or RPV LA that have advanced to phase III clinical trials
[178, 179], ProTides used in the clinic are characterized by high aqueous solubility
limiting their potential transformation into long acting nanosuspensions.
Considering the challenges and costs involved in the identification and
development of new chemical entities with high potency, acceptable safety profiles
as well as ease of formulation into long acting therapies, we chose to modify an
existing drug into lipophilic ProTide nanocrystals to provide prolonged intracellular
accumulation of 3TC-TP while improving drug biodistribution to infection sites
without compromising drug potency. We envisioned that controlled and sustained
intracellular delivery of 3TC monophosphate could potentially limit adverse effects
by maintaining drug levels within the therapeutic range.
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Limitations of NRTIs include shorter drug half-lives, variable PK profiles and
poor drug penetrance into cellular and tissue reservoirs of infection, thereby
increasing the likelihood of developing drug resistant virus strains [193, 194]. To
overcome these hurdles, kinase bypass strategies such as the phosphoramidate
ProTide technology have been explored and led to the discovery of potent antiviral
agents [173, 174]. However, prior studies in MDM demonstrated that application
of ProTide strategy to 3TC results in significant reduction in antiretroviral activity
of the modified compounds in comparison to the parent drug [195]. In addition, the
few reported examples of 3TC monophosphate analogs are either hydrolytically
unstable or susceptible to enzymatic dephosphorylation rendering such molecules
less efficacious [191, 192]. Therefore, clinical application of conventional ProTide
approaches to 3TC requires further optimization. We herein report on the design
and development of a long acting 3TC ProTide (M23TC) formulation (NM23TC)
with improved drug potency, lipophilicity and stability in plasma for enhanced
intracellular and tissue drug delivery. In the design of M23TC, phenylalanine was
selected based on inherent hydrophobicity and prior studies that demonstrated
significant enhancement in ProTide potency when combinations of aryl and
either L–alanine or L-phenylalanine methyl esters were used as phosphate
masking promoieties [177, 185]. The rationale for using a docosyl ester in our
synthesis was based on alcohol lipophilicity, inherent broad-spectrum antiviral
activity and synergistic effect on nucleoside analogs [186, 187]. Cellular exposure
to the lipid has been shown to be safe [186, 187].
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Development of sustained release aqueous suspension forms of hydrophilic
nucleoside reverse transcriptase inhibitor (NRTI) compounds is a significant
challenge. Additionally, the only available ARV ProTide (TAF) designed to
enhance drug potency is characterized by a shorter drug half-life and poor
physicochemical properties that limit encapsulation into long acting sustained
release formulations. Our initial attempts to use an ester prodrug approach to
formulate NRTIs provided only limited intracellular active TP levels [184]. With
these challenges in mind, we combined optimized ProTide and nanocrystal
strategies to produce a long acting slow effective release 3TC prodrug formulation
referred to as NM23TC. The prodrug formulation demonstrated a three-fold
improvement in EC50 in human MDM when compared to native 3TC. This is
notable since previous studies with phosphoramidate derivates of 3TC in MDM
and CEM CD4+ T cells demonstrated diminished potency when compared to
native 3TC treatment. The enhanced antiviral activity observed for NM23TC is
likely due to either improved cellular drug uptake and activation or potential
synergism between 3TC-TP and the docosanol masking group [186, 187].
The success of long acting HIV-1 formulations is dependent on efficient
delivery and sustained release of therapeutic concentrations of drug at cellular and
tissue

reservoirs

of

infection.

Specifically,

sustained

intracellular

drug

concentrations could disrupt viral replication cycle and prevent further
dissemination over time. To evaluate intracellular delivery and activation of
NM23TC, human MDM and CEM CD4+ T cells were used. Previous work from our
laboratory has shown that storage of nanoformulated antiretroviral drugs in
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endosomal compartments provides protection from drug metabolism [81, 82].
NM23TC significantly enhanced cellular drug uptake and retention compared to
native 3TC. To exert antiviral activity, M23TC must undergo intracellular
metabolism to form 3TC-TP [196]. The mechanism of activation and influence of
masking groups on ProTide bioactivation has previously been described [163,
197]. To affirm intracellular activation of M23TC, we quantified 3TC-TP levels in
MDM and CEM CD4+ T cells in parallel drug uptake and retention studies. In these
studies, NM23TC exhibited enhanced and sustained intracellular drug release
profiles with the active metabolite levels detectable for up to 30 days. Because of
enhanced 3TC-TP levels, NM23TC exhibited superior antiretroviral activity
compared to native 3TC as measured by HIV RT activity and HIV-1 p24 antigen
staining. The antiviral activity was sustained for 30 days after a single treatment
with NM23TC. Of importance, no cytotoxicity was observed at drug concentrations
used for cellular uptake and antiviral activity studies. These results demonstrate
that NM23TC enhances drug potency and sustained intracellular efficacy.
Given that effective treatment and prevention of HIV-1 is dependent on
achieving consistent therapeutic ART levels in plasma and tissues [198, 199], we
evaluated the PK and tissue distribution profiles of NM23TC in rats. A single
intramuscular injection of NM23TC provided sustained and high drug
concentrations in blood and tissues over one month. In contrast, drug
concentrations from native 3TC treatment fell below the limit of quantitation within
one day. High intracellular and tissue drug levels provided by NM23TC could
potentially translate into reduced dosage [158]. Of significance, NM23TC treated
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animals showed high 3TC-TP levels in lymph node cells and splenocytes at one
month compared to undetectable levels for the native drug treatment suggesting
efficient and sustained conversion of M23TC to its active form upon release from
nanocrystals. Overall, improvement in lipophilicity, plasma stability and tissue
distribution of M23TC has the potential to overcome limitations of the native drug
or previously described ProTide approaches. Previous studies have shown that
prodrugs that exhibit increased stability in plasma could enhance potency and
intracellular accumulation of nucleosides in vivo [174]. These data sets
demonstrate that transformation of 3TC from an oral daily dosage into potent long
acting formulations is achievable.
In summary, a novel long acting slow effective release NM23TC ProTide
nanoformulation was developed, exhibiting enhanced intracellular 3TC-TP
concentrations that paralleled potent antiretroviral activities for at least 30 days in
MDM and improved drug uptake in CD4+ T cells. The high concentrations of drug
observed in tissues of animals exposed to NM23TC could potentially translate to
improved efficacy and restrict low-level viral replication that occurs in lymphoid
tissues during combination antiretroviral therapy treatment. Also, the potency and
extended duration of action of NM23TC formulation could promote treatment
adherence. Future studies will evaluate in vivo anti-HIV efficacy of NM23TC
formulations in animal models of HIV-1 infection.
.
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Figure 5.1. Synthesis and characterization of M23TC: (A) Synthesis of aryl amino phosphochloridate
masking group as previously described [16]. (B) Conjugation of the masking group to 3TC using tBuMgCl base
in anhydrous THF to form M23TC in 65% yield. FTIR spectra of (C) 3TC and (D) M23TC. Absorption bands
at 2845 and 2852 cm-1 in M23TC spectrum correspond to C-H stretching of the docosyl ester. (E) M23TC
solubility in 1-Octanol and Water. (F) Degradation of M23TC (as % of initial) in plasma of four species.
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Figure 5.2. Physicochemical and biological characterization of M23TC and NM23TC: (A) MTT assay of MDM
24 hours after M23TC treatment over a concentration range of 1-200 μM. Results were normalized to
untreated control MDM. M23TC was found to be nontoxic up to 200 μM. Data are represented as mean+
SEM for n=3 samples per group. (B) CEM CD4+ T cell vitality using LiveDead Staining. CEM CD4+ T cells
plated in a 96 well plate at 100,000 cells/well were treated with a ranged of 3TC or M23TC concentrations
from 0.05-100μM. Data are represented as mean + SEM for n=3 samples per group. (C) EC50 was determined
in MDM by measuring RT activity in the supernatant for 3TC and NM3TC over a concentration range of 1nM1μM (EC50=6.2nM for NM23TC, 19.4nM for 3TC).

(D) EC50 was measured in CD4+ T cells over a

concentration range of 1nM-10μM by measuring RT activity of supernatant and normalized to % of positive
control (EC50=79.7nM for NM23TC, 35.4nM for 3TC). (E-H) TEM morphological evaluation in MDM and CEMCD4+ T CD4+ T cells. Cells were treated with 100μM NM23TC for 8 hours. Control cells (E and G) were
given no treatment and collected alongside treated cells (F and H).
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Figure 5.3.

M23TC nanoformulation (NM23TC) characterization and cell-nanoparticle interactions: (A)

M23TC was stabilized by a solution of P407 in PBS via high-pressure homogenization to form
nanosuspensions (NM23TC) that were characterized by size, PDI, and zeta potential. (B) TEM images of
NM23TC. MDMs treated for 24 hours with 100 µM NM23TC or 3TC measured as (C) drug (shown in red for
NM23TC and blue for 3TC) and conversion to (D) 3TC-TP. CEM-CD4+ T CD4+ cells treated for 8 hours with
10 µM NM23TC and (E) drug and (F) 3TC-TP levels were determined.
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Figure 5.4. NM23TC long-term cell-nanoparticle interactions and efficacy: M23TC levels after a single 8 hour
media treatment of 100 µM NM23TC or 3TC, followed by PBS wash and replacement with fresh medium over
30 days. (A) Drug and (B) 3TC-TP were quantified at days 1, 5, 10, 15, 20, 25, and 30 after treatment removal.
(C) Release of prodrug from MDM into culture medium at days 1, 5, 10, 15, 20, 25, and 30 after treatment
removal. Long-term antiretroviral efficacy was determined. At days 0, 1, 5,10, 15, 20, and 30 after an 8 hour
drug loading with 100µM 3TC or NM3TC MDM were challenged with HIV-1ADA at 0.1 MOI for 4 h. Untreated
infected and untreated uninfected cells served as positive and negative controls. Viral media was replaced
with fresh media and cells were cultured for an additional 10 days. Medium was collected for HIV reverse
transcriptase (RT) activity measurement; (D) corresponding cells were fixed in paraformaldehyde and stained
for HIV-1 p24 antigen (brown). (E) HIV RT activities were measured and expressed as a percentage of RT
activities in HIV-1 infected MDM. (F) RT activities in cells pre-treated with 100, 50, or 25 µM NM23TC and
infected 10-days later with HIV-1ADA.
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Figure 5.5. NM23TC pharmacokinetics: Sprague-Dawley rats were given a single IM injection of 75 mg/kg
3TC equivalents as NM23TC. (A) Prodrug concentrations in whole blood were measured at days 1,7,14, 21,
and 28. (B) Prodrug levels in liver were measured at days 1 and 28. Prodrug (red) and 3TC-TP (magenta)
levels in (C) lymph node, and (D) spleen were determined at days 1 and 28.
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1

Figure 5.6: Physicochemical characterization of M23TC (A) H-NMR of 3TC (red) and
13
31
M23TC (blue). (B) C-NMR of 3TC (red) and M23TC (blue). (C) P-NMR of 3TC. (D) Single
MS-scan of M23TC
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Figure 5.7. PK and toxicity testing in rodents: (A) Experimental Scheme for PK experiment with 75
mg/kg (or 3TC eq.) single IM injection. (B) Serum chemistry values after 14 days in rats. (C) After 14
days serum was collected and (C) monocytes, (D) neutrophils, and (E) lymphocytes were measured in
control and NM23TC (75 mg/kg eq.) injected animals.
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Chapter 6

A Long-Acting 3TC ProTide Nanoformulation
Suppresses HBV Replication in Humanized Mice
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6.1. Abstract
Lamivudine was modified (M23TC) into a lipophilic monophosphorylated
prodrug to extend the apparent drug half-life, improve potency and facilitate access
to viral replication sites. Lipid coated M23TC nanocrystals (NM23TC) were
prepared to further improve drug biodistribution and longevity. To evaluate antiHBV activity, TK-NOG mice were transplanted with human hepatocytes, and after
confirmation of human albumin (Alb) concentration in peripheral blood, animals
were infected intravenously with patient-derived serum samples containing ~106
copies/mL HBV DNA. Following confirmation of HBV DNA in peripheral blood,
eight animals were administered a single intramuscular dose of 75 mg/kg 3TC
equivalents of NM23TC and controls kept without drug. Levels of HBV DNA and
HBsAg in plasma were monitored over the 2 - 8-week experiment duration. At the
end of the study, liver tissues were analyzed for drug concentration, HBV DNA and
RNA by RT-PCR, and staining for human cells and viral proteins. A single
administration of NM23TC reduced HBV DNA by one log10 copies/ml up to four
weeks post drug treatment, without loss of human cells as assessed by Alb levels.
The results paralleled sustained drug levels in NP3TC treated animals.
6.2. Introduction
FDA approved monotherapy pre-exposure prophylaxis or treatment
regimens do not exist for 3TC in HIV-1. As shown in the previous chapter, a longacting lamivudine nanoformulation has been developed. Tissue and cellular 3TCTP levels extended over a month. Notably, lamivudine is widely prescribed for the
treatment of not only HIV-1 but HBV. HBV virus etiology is substantially different
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than HIV, however daily treatment is required, and includes similar limitations such
as short plasma drug elimination half-life, a weak barrier to resistance, and limited
drug penetration into viral sanctuaries. Though effective vaccine treatment against
HBV exists, over 250 million people worldwide live with chronic HBV. Treatment
of chronic HBV with NRTIs requires life-long therapy to suppress infection in
hepatocytes without elimination of cells with integrated DNA and HBs/HBx protein
expression. Notably, the primary active metabolite of 3TC (3TC-TP) is the same
against HIV-1 and HBV, as HBV also uses reverse transcriptase to generate viral
DNA (though the viral life cycle is much more complicated, involving covalently
closed circular DNA and multiple virally expressed antigens). Treatment with
NRTIs can prolong survival of chronic HBV patients compared to non-treated
patients in the inactive phase [200]. Lamivudine (3TC) remains the primary
affordable NRTI in resource-limited settings [201, 202].
Mice with chimeric humanized liver are a suitable model to test efficacy of
anti-HBV compounds ([203-209] as well anti-HCV drugs [210-213]. Herein, TKNOG mice with chimeric humanized liver infected with HBV were used to evaluate
the efficacy of long-acting 3TC formulation.
6.3. Materials and Methods
6.3.1. Ethical Treatment of Animals
Mice were maintained in a pathogen-free facility and treated humanely. All
mouse studies were conducted in strict accordance with the Guide for the Care
and Use of Laboratory Animals from University of Nebraska Medical Center
(UNMC). All experimental protocols were approved by the Animal Care and Use
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Committee of UNMC
6.3.2. Generation of a humanized liver TK-NOG mouse model
TK-NOG mice (NOD/Shi-scid IL-2 Rγcnull) expressing a herpes simplex virus
type 1 thymidine kinase transgene under regulation of the albumin gene promoter
were intrasplenically infused with 2 million human hepatocytes from the Lonza
(lot#4145) [214] (Figure 6.1).
6.3.3. NM23TC Dosing
NM23TC was prepared as described Chapter 5 and purified by differential
centrifugation. An initial formulation concentration of 10 mg/mL 3TC equivalents
was centrifuged at 4˚C for 10 minutes at 200 x g to remove excess polymer. The
supernatant was transferred and centrifuged again at 15000 x g for 20 minutes at
4˚C. The resulting size, PDI, zeta potential and concentration of the formulation
were measured as described in Chapter 5. The formulation was prepared
immediately before dosing. HBV infected mice were treated four weeks after
infection, when peripheral blood levels of HBV DNA had been established. Fifty
microliters of suspension were injected intramuscularly into the caudal thigh
muscle to achieve a dose of 75 mg/kg (3TC eq.) of NM23TC. After injection,
formulation integrity was monitored by DLS and drug concentration was again
determined. Animals were monitored for granuloma formation throughout the
study.
6.3.4. Serum Human Albumin
Serum human albumin levels [214] were measured in 50μL of serum and
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analysis performed using the Human Albumin ELISA Quantitation Set (E80-129,
Bethyl Laboratories Inc., Montgomery, TX).
6.3.5. Measurement of Blood HBV DNA and HBsAg levels
HBV DNA levels were measured using the COBAS TaqMan HBV Test
(Roche Diagnostics, Switzerland). The samples were diluted approximately 20fold and detection limits were 2240-3360 DNA copies/ml. Plasma HBsAg levels
were measured by ELISA using the QuickTiter Hepatitis B Surface Antigen ELISA
Kit (Cell Biolabs, Inc, VPK-5004, San Diego, CA) according to assay protocol.
6.3.6. RNA, DNA isolation, Real-time PCR and digital droplet PCR
Reagents for RNA isolation, cDNA synthesis and real time PCR were
purchased from Life Technologies and Applied Biosystems by Thermo Fisher
Scientific (Carlsbad &Foster city, CA). Primers and Probes were bought from
Integrated DNA Technologies, Inc (Coralville, IA).
Total RNA was isolated from liver cells by mixing Trizol with liver
homogenate in PBS. A 2-step procedure was applied, first reverse-transcribing
HBV RNA to cDNA using the high capacity reverse transcription synthesis kit.
cDNA then was amplified using TaqMan Universal Master Mix with fluorescentlabeled primers (TaqMan gene expression systems) in a Model 7500 qRT-PCR
thermal cycler. GAPDH cDNA was used to normalize RNA. Data were expressed
as the quantity of transcript (RQ).
HBV DNA levels were quantified by ddPCR. Total DNA was prepared using
the DNeasy Kit (Qiagen, Germany) according to the manufacturer’s protocol. The
concentrations of DNA were quantified using the QX200™ Droplet Digital™ PCR
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System (Bio-Rad, Hercules, CA). HBV sense and antisense primers were 5′- CGA
CGT GCA GAG GTG AAG-3′ and 5′- CAC CTC TCT TTA CGC GGA CT-3′
respectively. The HBV probe was 5′- /56-FAM/ATC TGC CGG /ZEN/ACC GTG
TGC AC-3’. Prepared droplets were transferred to a Bio Rad 96-well PCR plate
and underwent thermal cycling. After amplification, the ddPCR data were analyzed
using the QuantaSoft analysis software version 1.8 (Bio-Rad). The absolute
concentration of each sample was automatically reported by the ddPCR software.
6.4. Results
A single intramuscular administration of NM23TC suppressed HBV
replication and viral load in peripheral blood for up to 4 weeks and the presence of
prodrug in the liver tissue for this period was determined. In the set of experimental
animals with HBV DNA levels in peripheral blood <10 6 copies/ml and human
albumin levels in the range 0.5 – 2.5 mg/ml, a single intramuscular administration
of NM23TC formulation reduced the viral load by one log10 as shown on Figure
6.1.B. The levels of human albumin remained stable indicating drug treatment did
not alter total number of cells, (Figure 6.1.C) and animal weight was constant (not
shown). HBV infection was confirmed by the measurement of HBV DNA.
As expected, the levels of HBsAg remained constant (Figure 6.1.D). High
levels of prodrug in whole blood and liver in mice at 2 weeks (m3946 and m3942)
post treatment and 4 weeks post treatment (m3938 and m3942, shown in Figure
6.1.E F) mirrored HBV DNA viral load levels. In contrast, viral DNA remained
constant in non-treated control mouse (dotted line in figure 6.1.B). Viral rebound
at weeks 6 and 8 mirrored low to undetectable drug levels in plasma and liver.
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One animal had detectable 3TC-TP in liver at 8 weeks (not shown). In liver tissues
HBV DNA and RNA remained detectable in all tested animals (not shown).
6.5. Discussion
A long acting potent 3TC ProTide formulation was developed and
preliminary studies showed sustained anti-HBV activity in humanized mice for 4
weeks after single dosing. These results are promising for development of a longacting potent formulation of 3TC for the treatment and prevention of HBV and HIV
infections.
Though convincing as stand-alone data, HBV EC50 testing in hepatocytes
would provide a link between the formulation development, anti-HIV-1 activity, and
anti-HBV activity. This would allow for formulation optimization as well as prodrug
development in a more specific manner to HBV. A substantial degree of
formulation optimization could take place before being given to the mice. Direct
synthesis is ideal for scaling up formulations and may allow skipping formulation
purification steps. Every formulation at a certain concentration tends to aggregate
and becomes difficult to keep stable. An additional link would be created in
measuring and correlating liver 3TC-TP levels to M23TC levels at 2 weeks, 4
weeks, and 6 weeks following NM3TC administration in Balb/cJ mice.
More animals are needed with higher initial viral loads, and additional
control animals are needed to characterize anti-HBV activity. Single parenteral or
oral administration of 3TC in PBS could serve as a control, though effects may not
be seen past 2-3 days of injection given PK data of 75 mg/kg in Sprague Dawley
rats. IM injection of 75 mg/kg in rats showed limited 3TC levels in tissues and
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plasma at day 1. Notably, rats and mice have different metabolism and may
respond differently to treatments.
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Figure 6.1. Evaluation of 3TC formulation efficacy against HBV. (A) Experimental setup for HBV efficacy
in TK-NOG mice. (B) Inhibition of HBV replication and peripheral blood viral load (dotted line is control
mouse). Bold lines represent mean & SEM. P values were obtained by mixed effect analysis with Sidak’s
multiple comparison test (significance at 2 and 4 weeks). (C) Human albumin levels in blood (D) HBsAg
levels in plasma. (E) M23TC levels in (E) liver and (F) plasma in animals euthanized at 2 and 4 weeks post
treatment.
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Chapter 7
Summary, Conclusions, Future Directions, and
Application
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7.1. Summary, Conclusions, Future Directions, Application
The LATTE-2 study showing non-inferiority of IM dosed once monthly and
once every 2 months nanoformulated RPV and CAB, to triple therapy oral
antiretroviral regimens puts nanomedicine research in a clinical spotlight regarding
HIV. More FDA approved disease treatments using nanomedicines are being
approved each year, and the platform used in each of the projects herein is
undoubtedly a valuable one, with potential for clinical translation. This research,
taken as a whole, has furthered understanding of a prodrug nanoformulation
approach to antiretroviral therapy. This approach with different ARVs in our lab
has seen some major successes with integrase inhibitors [5, 6, 102, 103]. Here,
it has demonstrated that drugs with half-lives of less than 2 hours can be converted
to ones that have extended effects in vivo. Further, it has taken hydrophilic
clinically relevant drugs and reinvigorated the possibility of using them as longacting therapy by altering physicochemical structure, revisiting a well-vetted
chemical technology invented many years ago. The novelty is in the combination
of prodrugs and nanoformulation in these instances. Cellular permeability was
drastically improved in macrophages, and likely any kind of phagocytic cell. By
showing HBV suppression with monotherapy, the lamivudine project not only
provides evidence that a compound administered once daily can potentially be
given once monthly for viral suppression by monotherapy, it provides clues to
suspected mechanisms for this effect. The IM depot forms upon administration,
slowly releasing drug.

A certain amount of nanoformulation may leak into

circulation, an amount that is likely much smaller than is present in the depot
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formed. In vitro data showing month long antiviral inhibition and formation of active
metabolite matches squarely with the month-long inhibition seen in HBV mice. The
long-term intact prodrug release from macrophages indicates that phagocytic cells
in the liver may be taking up the nanoformulation and slowly releasing a clinically
effective amount of active prodrug which (as demonstrated by data in nonphagocytic CD4+ T cells) can be quickly taken up by almost any cell, in this case
by hepatocytes, and metabolized by these cells into the active triphosphate form.
This validates the use of macrophages as drug-carriers as well as drug-depots. In
the context of HBV infection, it would be interesting to determine the amount of
drug taken up by Kupffer cells in the liver to help pinpoint the mechanism of action.
With Epacadostat, a prodrug library as well as a nanoformulation library was
achieved. There is inherent value in developing such a library. The interplay
between academic institutions and the pharmaceutical industry encourages
exploration of new technologies for drug application in the academic arena, where
such formulations may find use. From this set of formulations, it was learned that
targeting moieties such as folic acid can enhance PK, even if the in vitro differences
are not pronounced between parent compound and formulation. The epacadostat
micelles and PLGA formulations produced stable particles, but highlight the impact
of drug loading and uptake, as drug was not taken up well in macrophages.
Purification via differential centrifugation proved useful in stabilization of the
nanoparticles, preventing aggregation. Many formulations were not stable and
aggregated quickly. Future experimentation with different formulation methods
may produce better results.
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In some instances, formulations with tremendous cellular uptake were
unusable due to instability after 1-2 days. When considered under a backdrop of
clinical translation, such formulations possess little value.

Any product that

aggregates or is not stable would practically face huge cost and implementation
challenges. The stability of the nanoformulations was tested in release media
(PBS and serum) and found that PBS solutions result in more prodrug being
released as parent compound. This observation confirmed the prodrug was not
only cleavable, but indicated hydrolysis was a significant cleavage mechanism.
We observed that parenteral injection produced the longest-lasting amounts
of drug in plasma and tissue after 24 hours. Various oral gavage solutions,
including the exact compound formulation given by the company that developed it,
resulted in formulations with a greater AUC (helped by initial release) but a lesser
long-term impact. Plasma kynurenine is a biomarker for IDO inhibition in cancer
and was seen to be lowered in regular mice with the injection paradigm. HIV-1
immune dynamics are much more complex, and different biomarkers are more
likely to be relevant for success.
Lack of difference in viral load levels in PD studies may be explained by
differences in epacadostat oral bioavailability brought about by enzymatic changes
from HIV-1. PK profiles of the IDOi-dosed animals measured by LC-MS/MS were
not directly comparable to the dosing regimen given in PD studies. This could be
a reason no change in the plasma kynurenine was observed. mRNA and western
blot would be valuable tools to help characterize enzymatic changes in the rodents
plasma and tissue cells, which affect plasma kynurenine. IDO is characterized in
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regular mice in literature, but a developing body of work is needed on humanized
mice, as well as the impact of IDO-2. Should we fail to show differences in viral
reservoir clearance, biodistribution changes shown in vivo should still provide a
novel platform to evaluate immunomodulatory changes effected with potent IDO
induction with respect to HIV. To look for such biodistribution changes we could
measure Treg/Th17 balance through FoxP3 and IL17 transcripts as well as mRNA
levels of mycovirus resistance protein 1 to determine if IDO inhibition on immune
cells is altered. Functionality of Tregs and TH17 cells can be tested using CFSE
proliferation assays. Different T cell activation in blood could be measured of cells
expressing Ki67[148].
The observations made do not rule out a role of IDO-1 in HIV-1 eradication
efforts, but do suggest use of combination antiretroviral therapy along with ‘kicking’
agents in a mouse model where the viral reservoir is characterized to extensive
degree (this may not be possible with current technologies) to accurately evaluate
any adaptive immune effects or long term counter-inflammatory effects the drug
may have. Of note is the difficulty the parent drug is encountering to pass phase
3 clinical trials for melanoma treatment, indicating a more complex immune system
interplay may be hindering its activity.
Previous work indicating a role in CTL response for IDOi can be revisited
with newer IDOi and different drug regimens.

To explore this possibility,

humanized mouse studies may provide better answers using a BLT (bone
marrow/liver/thymus) humanized mouse model with proven track record to
reiterate the human adaptive immune response to chronic HIV [215]. First, ART
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should be given to establish viral suppression and reservoir formation in tissue.
This reservoir seeding in terms of specific cell type and time to sequestration
should be characterized.

Subsequent work could optimize latency reversing

agents as treatment regimens, given that activating viral reservoirs (as confirmed
by increased systemic plasma viral RNA and DNA) may be necessary to see any
‘kill’ effect. Synergistic combinations of optimally dosed latency reversing agents
and IDOi might be co-administered in a maximally suppressively viral setting to
reactivate reservoir virus and mobilize an anergic adaptive immune response.
Upon treatment cessation, systemic and tissue viral rebound i.e. viral rebound
kinetics could be another way to measure IDO as a kill agent in HIV. Tissue
specific reservoir size in lymph, spleen, and bone marrow resting memory T cells
could be characterized using a viral outgrowth assay. CTL response could be
further characterized by cellular exhaustion markers PD-1 and CD107a on
peripheral CD8+ T cells.
Although epacadostat may not be justifiably advanced as an HIV-1
eradication agent given the current works, it does highlight the value for good
laboratory practices (GLP) and perhaps good manufacturing practices (GMP)
facilities in nanoformulation production.

Optimization of formulation production,

including polymer/drug ratios, stability assessments, as well as studies to assess
activity, can be carried out using GLP. This would minimize the effect of external
factors and provide more confidence in formulation reproducibility.

Further,

eventual testing and manufacturing of a drug could be carried out in GMP facilities.
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The tenofovir project validated ProTide technology to modify NRTIs to
improve drug loading into macrophages. TAF cannot be used in nanosuspensions
due to its hydrophilic nature. Therefore, a PLGA formulation was used to improve
uptake into cells. The robust differences between prodrug formulations and TAF
PLGA formulations promotes using ProTide nanoformulation to load drug payload
into macrophages. TAF is slowly phasing out TDF in clinics for both HIV and HBV
use. Not only will TAF nanoformulations become more relevant, but effective
delivery of TFV-DP to viral sanctuaries and tissues initially exposed to virus would
be relevant in pre-exposure prophylaxis studies.
Many TAF prodrugs did not produce expected or positive results in this
study. Long-lasting bonds between prodrug moieties and free functional groups
on the parent drug with this molecule may not produce usable prodrugs. TAF itself
is a single enantiomer and does not crystallize easily, so adding prodrug addition
may create multiple enantiomers, resulting in gel products. This may partially
explain lack of metabolism of the ester, carbamate, or other chemical bonds tried.
Other works from our lab have fluorescently labeled drug particles to monitor
localization within endosomal compartments.

This strategy may be useful in

examining where TAF prodrugs are going within a cell, as lysosomal cocompartmentalization would result in degradation of its P-N bond (due to pH of
4.5). The improved drug uptake from tenofovir prodrug nanoformulations may be
worth consideration of collaboration with a company, streamlining a process of
measuring TFV-DP and related toxicity from various TAF or TAF prodrugs
nanoformulations.
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There will be cases where improved concentrations of prodrug do not
correlate with lower EC50 and improved antiviral efficacy, most likely due to
inefficient or incomplete metabolism of prodrug to its monophosphate form. Vast
improvement of either EC50 or antiretroviral efficacy alone could be considered
enough to move prodrug candidates to the formulation stage. In the case of longacting prodrugs (greater than 10 days), long-term toxicity testing would be useful,
as endogenous nucleotide levels or lipid levels may become skewed as prodrug
stays within cells for an extended period. Long term cellular morphology and
confluency may also indicate toxicity.
Of the two TFV prodrugs developed, future work would focus on
nanoformulation advancement of these based on cellular potency, followed by
combination therapy testing in PreP studies with FTC in CD34+ humanized mice.
Development of sustained release aqueous suspension forms of hydrophilic
NRTIs is a significant challenge. The only approved ART ProTide (TAF) designed
to enhance drug potency is characterized by short drug half-life and unfavorable
physicochemical properties that limit encapsulation into long acting sustained
release formulations. Initial attempts to use an ester prodrug approach to formulate
3TC provided only limited intracellular active TP levels [100, 104]. The major
scientific finding from tenofovir work was the ability to increase prodrug in MDM
and provided direction in 3TC prodrug design to address intracellular TP issues.
Kinase bypass strategies such as the phosphoramidate ProTide technology
have been explored and led to the discovery of potent antiviral agents [173, 174].
However, prior studies in MDM demonstrated that application of ProTide strategy
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to 3TC results in significant reduction in antiviral activity of the modified compounds
in comparison to the parent drug[195]. In addition, the few reported examples of
3TC monophosphate analogs are either hydrolytically unstable or susceptible to
enzymatic dephosphorylation. In the design of M23TC, phenylalanine was
selected based on inherent hydrophobicity and prior studies that demonstrated
significant enhancement in ProTide potency when combinations of aryl and either
L–alanine or L-phenylalanine methyl esters were used as phosphate masking
promoieties[177, 185].

However, an approach using different amino acids may

produce stronger results. Further, the possibility of using a prodrug approach other
than ProTide technology, of which there are many, for subsequent nanoformulation
is strongly suggested by the positive results from the lamivudine works. The
rationale for using a docosyl ester in our synthesis was based on alcohol
lipophilicity, inherent broad-spectrum antiviral activity and synergistic effect on
nucleoside analogs[186, 187]. Again, prodrug construction is an area with infinite
possibilities. Works with different compounds in our lab have indicated improved
potency with shorter chain carbon lengths. Twenty-two chain carbons may be an
appropriate starting point for carbon chain length alteration.
Of note in the lamivudine work was that we were not able to improve the
EC50 of the prodrug itself. As demonstrated though, nanoformulations can improve
potency in certain cell types. Intracellular imaging would again provide benefit to
find where the formulation is localizing. Optimizing EC50 for specific cells types
other than macrophages (i.e. hepatocytes) would provide valuable information into
the overall importance of EC50 values into in vivo translation, depending on disease

132
model, and advance understanding of macrophage-based drug delivery. In the
case of HIV-1, it may be that optimization of 3TC-TP levels (in example superior
conversion compared to parent compound) in the suspected viral reservoir CD4+
memory T cells would provide a viable alternative in long-acting HIV therapeutic
regimens.
The aspect of evaluating NM23TC in humanized mice would require careful
thought. In addition to consideration of resistance issues and genotyping, the
peripheral blood mononuclear cell 3TC-TP levels in rats from NM23TC were
consistently near 100 fmoles/million cells. This is 10 times lower than clinical levels
seen in patients on chronic ART therapy, but rats may not be the best animal model
system. Additionally, blood spots are frequently used to measure 3TC-TP clinically
and, given that much more M23TC is partitioned in blood, this may be a more
accurate measure [216].

Rabbits, mice, and dogs are viable alternatives for

pharmacokinetic works.

The hallmark of effective HIV drug treatment is the

reduction of viral load by increasing drug in plasma. Of note, prodrugs in circulation
that are hydrophobic may possess substantially higher protein binding and alter
the apparent already-known EC50 of a parent compound (bound protein would
theoretically be unable to enter cells).

Nanoformulations however, especially

parenteral injections that form depots, do not follow typical compartmental kinetics.
Initial studies by our lab have examined how viral reservoirs are formed in
humanized mice, and in which cell type they exist [131]. Follow on experiments
could measure tissue levels, correlate integrated viral DNA (and potentially viral
RNA) to not only tissue levels but specific cell types. Possessing drug candidate
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information about penetrance into cellular specific reservoirs in humanized mouse
models would be incredibly value information and may be a step towards
eradication. Forays by our lab into long-acting slow effective release antiretroviral
therapy (LASER ART) often produce high prodrug tissue levels over long time
periods. Some clinical translation may come from humanized mouse studies.
Certainly, PK testing of individual drugs, followed by PK and PD testing of
drug combinations will bear the most scientifically useful information for advancing
this platform. Parenteral injections can form depots at site of injection, especially
with hydrophobic drug nanoformulations. Formulation optimization based on in
vivo interaction with tissue, perhaps by evaluation of ex vivo release kinetics, may
lead to more effective formulations. In the case of ex vivo release kinetics, by
evaluating prodrug or nanoformulation dissolution rates and conversion to active
form in S9 fractions (the product of a tissue homogenate isolated by centrifuging
at 900 x g for 20 minutes, containing cell cytosol and microsomes).

Alternative

routes of administration could be looked at to improve pharmacokinetic profiles.
Subcutaneous or IM injections in example may produce substantially different
profiles. As PK modeling for nanoformulations advances, more successful testing
of nanoformulation prodrugs would follow. PK modeling is complex, and future
collaborations with labs or companies experienced in these types of models may
allow development of a predictive model.
These works have potential to address adherence issues in antiviral
disease states through development of long-acting formulations. Lamivudine may
not be as clinically relevant as tenofovir but saw the most successfully advanced

134
iteration of nanoformulation technology in these works. Comparisons of prodrug
to parent drug have slight bias, as the parent drug was designed for oral therapy,
and not intended to form depots. Partnering with pharmaceutical industry may
provide resources to accelerate future development. Future works might also
address HIV-HBV coinfection with monotherapy or combined therapy [217].
Additionally, any disease context in which adherence is a problem could potentially
see solvation through nanoformulation, or nanoformulated prodrug platforms. This
has been seen in schizophrenic patients where injections were necessary due to
the nature of the illness [218]. Nanomedicines in some cases are given orally.
Though this would change the nature of the prodrug and formulation design
drastically, such future works might examine oral or alternative routes of injections
for potent nanoformulations.
Though outside the scope of this work, from a broad clinical perspective, it
may be all the tools are present for ending the HIV-epidemic, despite lacking a
functional or sterilizing cure. Efforts in certain countries like the Philippines [219]
have reduced the HIV transmission rates greatly, largely through coordinated
intelligent efforts by doctors, social workers, and the community to use available
treatments. Recently the United States has purportedly taken such an approach.
A stark decline in the selective ‘hotspots’ of HIV over the next several years would
be an indicator of success. If the hurdles if diagnosing people with HIV and getting
them to adhere to regimens can be addressed (as reported by the Ryan White
Foundation [220, 221]), then the HIV epidemic may be solvable.
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